Klk5 / 7 + il-13 targeting antibodies and uses thereof

Abstract

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to IL-13 or receptor thereof.

Description

KLK5 / 7 + IL-13 TARGETING ANTIBODIES AND USES THEREOFRELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application, U.S.S.N. 63 / 578,959, filed August 25, 2023, U.S. Provisional Application, U.S.S.N. 63 / 549,274, filed February 2, 2024, and U.S. Provisional Application, U.S.S.N. 63 / 671,694, filed July 15, 2024, the entire contents of each of which are incorporated herein by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (A140770004WO00-SEQ-LJG.xml; Size: 241,765 bytes; and Date of Creation: August 22, 2024) is herein incorporated by reference in its entirety.BACKGROUND

[0003] Skin contains tissue structure and cells, such as epithelial cells and immune cells, that together provide a functional and physical barrier that serves an important role in preventing allergen penetration into the body and responding to pathogens. Kallikrein (KLK) enzymes regulate desquamation and innate immunity to support skin homeostasis and wound healing. In a healthy skin, the outermost layer of the epidermis is regularly shed through a KLK driven proteolytic cascade resulting in the degradation of comeodesmosomes and desquamation. KLK5 is understood to be a main activator of this proteolytic cascade. Autoactivated KLK5 enzymatically converts proKLK7 and proKLK14 to active forms and stimulates a positive feedback loop that, via KLK14, leads to the production of more proKLK5. These KLK enzymes are kept in check by endogenous serine protease inhibitors, such as lymphoepithelial Kazal-type-related inhibitors. Dysregulation of KLKs, including KLK5 and KLK7, is associated with skin disorders, inflammatory diseases, and cancer. For example, hyperactive kallikrein 5 and 7 cause both genetic and spontaneous epidermal barrier disorders (e.g., Netherton syndrome, eosinophilic esophagitis, atopic dermatitis).SUMMARY

[0004] Certain aspects of the disclosure relate to a recognition that loss of balance between endogenous KLK proteases and associated protease inhibitors causes barrier dysfunction andinduces inflammation (as illustrated in FIG. 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. Moreover, elevated activity of T helper 2 (Th2) cytokines (such as, for example, IL-13) can further drive inflammation and contribute to barrier dysfunction and related conditions (as illustrated in FIG. 2). In some embodiments, compositions and methods provided herein are useful for inhibiting KLK5 / KLK7 and IL- 13 signaling to improve barrier function and reduce inflammation, which ameliorates disease severity.

[0005] Further, aspects of the present disclosure provide multispecific antibodies comprising at least one antigen- specific binding site that specifically binds KLK5 and KLK7 and at least one antigen- specific binding site that specifically binds to IL- 13 or receptor thereof. In certain embodiments, such multispecific antibodies are configured such that they comprise at least one arm binds the active site of KLK5 and KLK7, and at least one other arm binds to IL- 13 or IL- 13 receptor (IL-13R). In some embodiments, such multispecific antibodies are advantageous because they inhibit both KLK5 / 7 activity and IL- 13 activity in a single molecule. In some embodiments, with respect to KLK5 / 7 binding site within the multispecific antibody (e.g., bispecific antibody), such antibodies bind specifically to the active forms rather than the proforms of the enzymes. In some embodiments, methods and related compositions, and antibody for use in methods are provided that are useful for inhibition of KLK5 and KLK7 along with IL- 13 activity for purposes of improving barrier function and reducing inflammation, which ameliorates disease severity. In particular, aspects of the disclosure provide bispecific antibodies in which one arm comprises an antigen- specific binding site of a dual inhibitor antibody targeting KLK5 and KLK7 (referred to as anti-KLK5 / KLK7 antibodies), which has high binding affinity and specificity to the active sites of both KLK5 and KLK7, and in which the other arm specifically binds to and inhibits activity of IL- 13 or receptor thereof (referred to as an anti-KLK5 / KLK7 + IL- 13 bispecific antibody). Accordingly, in some embodiments, the disclosure provides methods and related antibody compositions for treating conditions associated with KLK5 and KLK7 dysregulation and / or aberrant Th2 cytokine activity, such as Netherton Syndrome, atopic dermatitis (with and without filaggrin mutations), eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), asthma (e.g., KLK5 related asthma), and ichthyosis vulgaris.

[0006] In some embodiments, the present disclosure provides a bispecific antibody that comprises at least one antigen- specific binding site of a dual inhibitor antibody targeting KLK5 and KLK7, and at least one antigen- specific binding site that specifically binds andinhibits IL- 13 (referred to as an anti-KLK5 / KLK7 + IL- 13 targeting bispecific antibody). Accordingly, in some embodiments, the disclosure provides methods and related antibody compositions for treating conditions associated with KLK5 and KLK7 dysregulation, in which Th2 cytokines, such as IL- 13, also play a role in pathogenesis, such as Netherton Syndrome, atopic dermatitis (with and without filaggrin mutations), eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), asthma (e.g. , KLK5 related asthma), and ichthyosis vulgaris.

[0007] In some aspects, the disclosure provides a bispecific antibody comprising an antigenspecific binding site that specifically binds KLK5 and KLK7 and an antigen- specific binding site that specifically binds to IL- 13 or a receptor thereof. In some embodiments, the antigenspecific binding site that specifically binds KLK5 and KLK7 binds to the active sites of KLK5 and KLK7 and inhibits activity of the enzymes. In some embodiments, the antigenspecific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the antibodies listed in Table la and Table lb.

[0008] In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1, a HC CDR2, a HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 7, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 13, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 17, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 21, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.

[0009] In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 1, a HC CDR2 having the amino acid sequence of SEQ ID NO: 2, a HC CDR3 having the amino acidsequence of SEQ ID NO: 3, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 10, a HC CDR3 having the amino acid sequence of SEQ ID NO: 11, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 15, a HC CDR3 having the amino acid sequence of SEQ ID NO: 16, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 18, a HC CDR2 having the amino acid sequence of SEQ ID NO: 19, a HC CDR3 having the amino acid sequence of SEQ ID NO: 20, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.

[0010] In some embodiments, the antigen- specific binding site that specifically binds to KLK5 and KLK7 is of a VH and / or a VL of any one of the antibodies listed in Table la.

[0011] In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 13, and a VL comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, the antigen- specific binding site that specifically binds KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 21, and a VL comprising the amino acid sequence of SEQ ID NO: 14.

[0012] In some embodiments, the antigen- specific binding site that specifically binds to IL- 13 or a receptor thereof comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LCCDR2, and / or LC CDR3 of any one of the antibodies listed in Table 2.

[0013] In some embodiments, the antigen- specific binding site that specifically bindsIL- 13 or IL-13R comprises a HC CDR1, a HC CDR2, a HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 53, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 54. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 33. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL- 13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 74, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 75. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL- 13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 94, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 95. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL- 13R comprises HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 114, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 115. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL- 13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 134, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL- 13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 657, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 658.

[0014] In some embodiments, the antigen- specific binding site that specifically binds11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 55, a HC CDR2 having the amino acid sequence of SEQ ID NO: 56, a HC CDR3 having the amino acid sequence of SEQ ID NO: 57, a LC CDR1 having the amino acid sequence of SEQ ID NO: 58, a LC CDR2 having the amino acid sequence of SEQ ID NO: 59, and a LC CDR3having the amino acid sequence of SEQ ID NO: 60. In some embodiments, the antigenspecific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 61, a HC CDR2 having the amino acid sequence of SEQ ID NO: 62, a HC CDR3 having the amino acid sequence of SEQ ID NO: 63, a LC CDR1 having the amino acid sequence of SEQ ID NO: 64, a LC CDR2 having the amino acid sequence of SEQ ID NO: 65, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 66. In some embodiments, the antigen- specific binding site that specifically binds fl- 13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 67, a HC CDR2 having the amino acid sequence of SEQ ID NO: 68, a HC CDR3 having the amino acid sequence of SEQ ID NO: 69, a LC CDR1 having the amino acid sequence of SEQ ID NO: 70, a LC CDR2 having the amino acid sequence of SEQ ID NO: 71, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antigenspecific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 34, a HC CDR2 having the amino acid sequence of SEQ ID NO: 35, a HC CDR3 having the amino acid sequence of SEQ ID NO: 36, a LC CDR1 having the amino acid sequence of SEQ ID NO: 37, a LC CDR2 having the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 39. In some embodiments, the antigen- specific binding site that specifically binds II- 13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 40, a HC CDR2 having the amino acid sequence of SEQ ID NO: 41, a HC CDR3 having the amino acid sequence of SEQ ID NO: 42, a LC CDR1 having the amino acid sequence of SEQ ID NO: 43, a LC CDR2 having the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 45. In some embodiments, the antigenspecific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 46, a HC CDR2 having the amino acid sequence of SEQ ID NO: 47, a HC CDR3 having the amino acid sequence of SEQ ID NO: 48, a LC CDR1 having the amino acid sequence of SEQ ID NO: 49, a LC CDR2 having the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 51. In some embodiments, the antigen- specific binding site that specifically binds fl- 13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 76, a HC CDR2 having the amino acid sequence of SEQ ID NO: 77, a HC CDR3 having the amino acid sequence of SEQ ID NO: 78, a LC CDR1 having the amino acid sequence of SEQ ID NO: 79, a LC CDR2 having the amino acid sequence of SEQ ID NO: 80, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 81. In some embodiments, the antigen-specific binding site that specifically binds IL- 13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 85, a LC CDR2 having the amino acid sequence of SEQ ID NO: 86, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 87. In some embodiments, the antigen- specific binding site that specifically binds fl- 13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 88, a HC CDR2 having the amino acid sequence of SEQ ID NO: 89, a HC CDR3 having the amino acid sequence of SEQ ID NO: 90, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of SEQ ID NO: 92, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93. In some embodiments, the antigenspecific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 96, a HC CDR2 having the amino acid sequence of SEQ ID NO: 97, a HC CDR3 having the amino acid sequence of SEQ ID NO: 98, a LC CDR1 having the amino acid sequence of SEQ ID NO: 99, a LC CDR2 having the amino acid sequence of SEQ ID NO: 100, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 101. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 102, a HC CDR2 having the amino acid sequence of SEQ ID NO: 103, a HC CDR3 having the amino acid sequence of SEQ ID NO: 104, a LC CDR1 having the amino acid sequence of SEQ ID NO: 105, a LC CDR2 having the amino acid sequence of SEQ ID NO: 106, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 108, a HC CDR2 having the amino acid sequence of SEQ ID NO: 109, a HC CDR3 having the amino acid sequence of SEQ ID NO: 110, a LC CDR1 having the amino acid sequence of SEQ ID NO: 111, a LC CDR2 having the amino acid sequence of SEQ ID NO: 112, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 113. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 116, a HC CDR2 having the amino acid sequence of SEQ ID NO: 117, a HC CDR3 having the amino acid sequence of SEQ ID NO: 118, a LC CDR1 having the amino acid sequence of SEQ ID NO: 119, a LC CDR2 having the amino acid sequence of SEQ ID NO: 120, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 121. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13Rcomprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 122, a HC CDR2 having the amino acid sequence of SEQ ID NO: 123, a HC CDR3 having the amino acid sequence of SEQ ID NO: 124, a LC CDR1 having the amino acid sequence of SEQ ID NO: 125, a LC CDR2 having the amino acid sequence of SEQ ID NO: 126, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 127. In some embodiments, the antigenspecific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 128, a HC CDR2 having the amino acid sequence of SEQ ID NO: 129, a HC CDR3 having the amino acid sequence of SEQ ID NO: 130, a LC CDR1 having the amino acid sequence of SEQ ID NO: 131, a LC CDR2 having the amino acid sequence of SEQ ID NO: 132, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 133. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 136, a HC CDR2 having the amino acid sequence of SEQ ID NO: 137, a HC CDR3 having the amino acid sequence of SEQ ID NO: 138, a LC CDR1 having the amino acid sequence of SEQ ID NO: 139, a LC CDR2 having the amino acid sequence of SEQ ID NO: 140, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 141. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 142, a HC CDR2 having the amino acid sequence of SEQ ID NO: 143, a HC CDR3 having the amino acid sequence of SEQ ID NO: 144, a LC CDR1 having the amino acid sequence of SEQ ID NO: 145, a LC CDR2 having the amino acid sequence of SEQ ID NO: 146, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 147. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 148, a HC CDR2 having the amino acid sequence of SEQ ID NO: 149, a HC CDR3 having the amino acid sequence of SEQ ID NO: 150, a LC CDR1 having the amino acid sequence of SEQ ID NO: 151, a LC CDR2 having the amino acid sequence of SEQ ID NO: 152, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 153. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 655, a HC CDR2 having the amino acid sequence of SEQ ID NO: 41, a HC CDR3 having the amino acid sequence of SEQ ID NO: 42, a LC CDR1 having the amino acid sequence of SEQ ID NO: 43, a LC CDR2 having the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 45. In some embodiments, the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises a HC CDR1 having the aminoacid sequence of SEQ ID NO: 656, a HC CDR2 having the amino acid sequence of SEQ ID NO: 47, a HC CDR3 having the amino acid sequence of SEQ ID NO: 48, a LC CDR1 having the amino acid sequence of SEQ ID NO: 49, a LC CDR2 having the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 51.

[0015] In some embodiments, the antigen- specific binding site that specifically binds IL-13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 53 and a VL comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 32, and a VL comprising the amino acid sequence of SEQ ID NO: 33. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 74, and a VL comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 94, and a VL comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the antigenspecific binding site that specifically binds IL- 13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 114, and a VL comprising the amino acid sequence of SEQ ID NO: 115. In some embodiments, the antigen- specific binding site that specifically binds IL-13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 134, and a VL comprising the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 657, and a VL comprising the amino acid sequence of SEQ ID NO: 658.

[0016] In some embodiments, the antigen- specific binding site that specifically binds to IL-13 or a receptor thereof is of a VH and / or a VL of any one of the antibodies in Table 2. In some embodiments, the bispecific antibody retains the binding affinity to KLK5 and KLK7 of no more than 20% difference relative to an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the bispecific antibody retains the binding affinity of no more than 20% difference to IL- 13 signaling relative to an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the bispecific antibody retains at least 80% of inhibitory activity to KLK5 and KLK7 relative to an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the bispecific antibody retains at least 80% of inhibitory activity to IL- 13 signaling relative toan anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

[0017] In some embodiments, the disclosure provides a composition comprising a bispecific antibody provided herein and an acceptable carrier.

[0018] In some embodiments, the disclosure provides a method comprising administering a bispecific antibody provided herein or a composition provided herein to a subject. In some embodiments, the subject has a skin barrier defect.

[0019] In some embodiments, the disclosure provides a method of treating a skin barrier defect, the method comprising administering to a subject an effective amount of a bispecific antibody provided herein or a composition provided herein. In some embodiments, the skin barrier defect is associated with Netherton syndrome, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), dry skin, asthma (KLK5 specifically), ichthyosis vulgaris, or itch or chronic itch.

[0020] In some embodiments, the subject has atopic dermatitis. In some embodiments, administration of an antibody provided herein or a composition provided herein reduces ear thickness by more than 30% relative to a subject administered an anti- KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces ear thickness by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti- KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin excoriation / erosion by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin scaling / dryness by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin scaling / dryness by more than 30% relative to a subject administered an anti-IL-13 antibodythat comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin edema by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody. In some embodiments, the administration reduces skin edema by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

[0021] The foregoing and other aspects, implementations, acts, functionalities, features and embodiments of the present teachings can be more fully understood from the following description in conjunction with the accompanying drawings.BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate certain embodiments, and together with the written description, serve to provide non-limiting examples of certain aspects of the compositions and methods disclosed herein.

[0023] FIG. 1 is a diagram showing aberrant protease activation (e.g., aberrant KLK5, KLK7, and KLK14) activation leading to skin barrier defect associated diseases.

[0024] FIG. 2 is a graph showing that, in conditions related to epidermal barrier dysfunction, elevated KLK5 / KLK7 activity leads to Th2 cell activation, which further increases KLK5 / KLK7 activity.

[0025] FIGs. 3A-3B are graphs showing that inhibiting KLK5 / KLK7 and Th2 signaling has beneficial effects beyond an anti-IL4R antibody in Nc / Nga model for atopic dermatitis. FIG. 3A shows that mice treated with KLK5 / KLK7-Dual-Ab4 have further reduced ear thickness compared to mice treated with the anti-IL-4R antibody. FIG. 3B shows mice treated with KLK5 / KLK7-Dual-Ab4 have reduced clinical skin score compared to treating with the anti-IL-4R antibody.

[0026] FIGs. 4A-4I relate to binding affinity of an exemplary anti-KLK5 / KLK7 + IL-13 bispecific antibody (referred to as K13-0004). FIGs 4A-4C show KD values of binding to KLK5 (FIG. 4A), KLK7 (FIG. 4B), and IL-13 (FIG. 4C). FIGs. 4D-4H show the inhibition of KLK5 (FIG. 4D; comparison to an exemplary anti-KLK5 / KLK7 dual antibody in FIG.4E), KLK7 (FIG. 4F; comparison to an exemplary anti-KLK5 / KLK7 dual antibody in FIG. 4G), IL- 13 (FIG. 4H), and the extracellular matrix protein (ECM) periostin (FIG. 41).

[0027] FIGs. 5A-5D relate to the abrogation of KLK5- and KLK7 -mediateddisruption of primary human keratinocyte barrier disruption. FIGs. 5A shows the trans- epithelial resistance (TEER) follow treatment with anti-KLK5 / KLK7 + IL- 13 bispecific antibodies at varying concentrations (FIG. 5A) or anti-KLK5 / KLK7 dual antibodies at varying concentrations (FIG. 5B). FIGs. 5C-5D show the migration of FITC-Dextran dye following treatment with anti-KLK5 / KLK7 + IL- 13 bispecific antibodies at varying concentrations (FIG. 5C) or anti-KLK5 / KLK7 dual antibodies at varying concentrations (FIG. 5D).DETAILED DESCRIPTION

[0028] The present disclosure, at least in part, is based on the development of a bispecific antibody comprising one arm that comprises an antigen binding site of a dual inhibitor antibodies and variants thereof targeting KLK5 and KLK7, and one other arm that comprises an antigen binding site of an anti-IL13 or anti-IL-13R antibody (referred to as anti- KLK5 / KLK7 + IL- 13 bispecific antibody). These dual inhibitor antibodies target KLK5 and KLK7 via a common distinct antigen- specific binding site. Such dual inhibitor antibodies have high binding affinity and specificity to KLK5 and KLK7 (anti-KLK5 / KLK7 antibodies). In some embodiments, bispecific antibodies are provided in which one arm comprises an antigen- specific binding site of a dual inhibitor antibody targeting KLK5 and KLK7 and in which the other arm specifically binds to and inhibits activity of IL- 13. Also provided are methods of using the anti-KLK5 / KLK7 + IL- 13 bispecific antibodies and their variants in research, diagnostic / detection, and therapeutic applications, and anti-KLK5 / KLK7 + IL- 13 bispecific antibodies for use in such methods.

[0029] The foregoing and other aspects, implementations, acts, functionalities, features and embodiments of the present teachings can be more fully understood from the following description in conjunction with the accompanying drawings.I. Definitions

[0030] Administering: As used herein, the terms “administering” or “administration” means to provide an antibody or a composition thereof to a subject in a manner that is physiologically and / or pharmacologically useful (e.g., to treat a condition in the subject).

[0031] Affinity Matured Antibody: The term “Affinity Matured Antibody” is used herein to refer to an antibody with one or more alterations in one or more CDRs, which resultin an improvement in the affinity (e.g., KD, kd or ka) of the antibody for a target antigen compared to a parent antibody, which does not possess the alteration(s). Exemplary affinity matured antibodies may have nanomolar or even picomolar affinities for the target antigen in some embodiments. A variety of procedures for producing affinity matured antibodies are available, including the screening of a combinatory antibody library that has been prepared using bio-display. For example, Marks et al., BioTechnology, 10: 779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described by Barbas et al., Proc. Nat. Acad. Sci. USA, 91: 3809-3813 (1994); Schier et al., Gene, 169: 147-155 (1995); Yelton et al., J. Immunol., 155: 1994-2004 (1995); Jackson et al., J. Immunol., 154(7): 3310-3319 (1995); and Hawkins et al, J. Mol. Biol., 226: 889-896 (1992). Selective mutation at selective mutagenesis positions and at contact or hypermutation positions with an activity-enhancing amino acid residue is described in U.S. Pat. No. 6,914,128 Bl.

[0032] Antibody: As used herein, the term “antibody” refers to a polypeptide that comprises at least one immunoglobulin variable domain, which comprises at least one distinct antigen- specific binding site, or a portion of an immunoglobulin variable domain (such as a paratope or portion thereof) that comprises at least one distinct antigen- specific binding site. In some embodiments, an antibody comprises at least one distinct antigenspecific binding site that specifically binds to the active site of an enzyme. In some embodiments, an antibody is an IL- 13 targeting antibody that comprises at least one antigenspecific binding site that specifically binds to IL- 13 or a receptor thereof. In some embodiments, an antibody is a full-length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a F(ab')2 fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a multi- specific antibody e.g., a bispecific antibody). In some embodiments, an antibody is a nanobody derived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgGl, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgAl, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region or domain (abbreviated herein as VH), and / or a light (L) chain variable region or domain (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain. Animmunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. In some embodiments, a heavy chain constant domain of an immunoglobulin comprises an Fc region. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (a), delta (A), epsilon (e), gamma (y) or mu (p) heavy chain. In some embodiments, an antibody described herein comprises a human gamma 1 CHI, CH2, and / or CH3 domain. In some embodiments, the amino acid sequence of the antibody comprises the amino acid sequence of a human gamma (y) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, an antibody comprises a heavy chain that comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the variable chain constant regions provided herein. In some embodiments, an antibody comprises a light chain that comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the light chain constant regions provided herein. In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and / or phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N- acetylgluco s amine unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a polypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g.,Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[0033] Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0034] Bispecific Antibody: As used herein, the term “bispecific antibody” refers to an antibody that comprises two distinct antigen- specific binding sites or two linked (covalently or non-covalently) antibodies that, combined, comprise two distinct antigenspecific binding sites. Non-limiting examples of bispecific antibody formats or architectures are provided in Eabrijn, AF, et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery volume 18, pages 585-608 (2019) and Brinkmann U and Kontermann EE, The making of bispecific antibodies, MAbs. 2017 Feb / Mar;9(2): 182-212, the entire contents of each of which are incorporated herein by reference in their entireties.

[0035] CDR: As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region or heavy chain variable domain (VH) and a light chain variable region or light chain variable domain (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known in the art, for example, by the Kabat definition, the IMGT definition, theChothia definition, the AbM definition, and / or the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; IM GT®, the international ImMunoGeneTics information system® http: / / www.imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P, Nucleic Acids Res., 29:207- 209 (2001); Lefranc, M.-P, Nucleic Acids Res., 31:307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [[Epub]], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. et al., Nucleic Acids Res., 43:D413-422 (2015); Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk / abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[0036] In certain embodiments, there are three CDRs in each of the variable regions of a heavy chain and a light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as LI, L2 and L3 or Hl, H2 and H3 where the "L" and the "H" designate the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (EASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732- 45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methodsused herein may utilize CDRs defined according to any of these systems, although preferred embodiments use Kabat or Chothia defined CDRs.

[0037] CDR-grafted antibody: As used herein, the term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and / or VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human CDR sequences.

[0038] Chimeric antibody: As used herein, the term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[0039] Complementary: As used herein, the term “complementary” refers to the capacity for precise pairing between two nucleotides or two sets of nucleotides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleotides or two sets of nucleotides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (e.g., an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non- Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine- type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[0040] Conservative amino acid substitution: As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocolsin Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0041] Cross-reactive: As used herein, the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human KLK5 and nonhuman primate KLK5, a human KLK7 and non-human primate KLK7) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross-reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross -reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[0042] Dual Inhibitor Antibody: As used herein, the term “dual inhibitor antibody” refers to an antibody that targets at least two (e.g., two, three) different antigens via a common distinct antigen- specific binding site and inhibits activity of those antigens. In some embodiments, a dual inhibitor antibody targets at least two different proteins (e.g., expressed from two different genes (e.g., endogenous genes, e.g., homologues, paralogues) via a common distinct antigen- specific binding site and inhibits activity of the at least two different proteins (e.g., enzymes, such as proteases). In some embodiments, a dual inhibitor antibody targets at least two different proteases (e.g., expressed by two different endogenous genes, e.g., KLK5 and KLK7) via a common distinct antigen- specific binding site and inhibits activity of the at least two different proteases. In some embodiments, the common distinct antigen- specific binding site binds to a similar (e.g., homologous) domain shared between or among the at least two different antigens. For example, in some embodiments, the common distinct antigen- specific binding site binds to a similar (e.g., homologous) catalytic domain or substrate binding site shared between or among the at least two different enzymes, e.g., proteases. In some embodiments, the common distinct antigen- specific binding site of a dual inhibitor antibody comprises amino acids of one or more complementarity determining regions of the antibody. In some embodiments, the common distinct antigen- specific binding site of a dual inhibitor antibody is within a heavy chain variable region and / or a light chainvariable region of the antibody. In some embodiments, the common distinct antigen- specific binding site of a dual inhibitor antibody comprises one or more complementarity determining regions of a heavy chain variable region and / or a light chain variable region of the antibody. In some embodiments, the common distinct antigen- specific binding site of a dual inhibitor antibody comprises HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 of a heavy chain variable region and a light chain variable region of the antibody. In some embodiments a dual inhibitor antibody specifically binds to two different proteins expressed from two different genes (e.g., KLK5 and KLK7).

[0043] Effective Amount: As used herein, “an effective amount” refers to the amount of each active agent (e.g., anti-KLK5 / KLK7 + IL- 13 bispecific antibody) required to confer a desired effect (e.g., a therapeutic effect on the subject), either alone or in combination with one or more other active agents. In some embodiments, the therapeutic effect is reduced KLK5 and / or KLK7 activity and / or reduced IL- 13 activity and / or alleviated disease (e.g., Netherton syndrome, eosinophilic esophagitis and atopic dermatitis) or related symptoms, e.g., improved barrier function.

[0044] Framework: As used herein, the term "framework" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4.Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred to by others, represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions, and FRs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[0045] Human antibody: The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutationsintroduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0046] Humanized antibody: As used herein, the term "humanized antibody" refers to antibodies which comprise heavy and light chain variable region sequences from a nonhuman species (e.g., a mouse) but in which at least a portion of the VH and / or VL sequence has been altered to be more "human-like", i.e., more similar to human germline variable sequences. One type of humanized antibody is a CDR- grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding nonhuman CDR sequences. In one embodiment, humanized antibodies are provided. Such antibodies may be generated by obtaining murine monoclonal antibodies using traditional hybridoma technology followed by humanization using in vitro genetic engineering, such as those disclosed in Kasaian et al PCT publication No. WO 2005 / 123126 A2.

[0047] Humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some embodiments, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Antibodies may have Fc regions modified as described in WO 99 / 58572. Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five, six) which are altered with respect to the original antibody, which are also termed one or more CDRs derived from one or more CDRs from the original antibody. Humanized antibodies may also involve affinity maturation.

[0048] In some embodiments, humanization is achieved by grafting the CDRs (e.g., as shown in Tables la, or lb) into the human variable domains (e.g., IGKV1-NL1*O1 and IGHVl-3*01 human variable domain). In some embodiments, an antibody of the present disclosure is a humanized variant comprising one or more amino acid substitutions (e.g., in the VH framework region) as compared with any one of the VHs listed in Tables la, or lb and / or one or more amino acid substitutions (e.g., in the VL framework region) as compared with any one of the VLs listed in Tables la, or lb.

[0049] Isolated antibody: An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities. An isolated antibody may, however, have cross -reactivity to other antigens, in some embodiments. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0050] Kabat numbering: As used herein, the terms "Kabat numbering", "Kabat definitions" and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[0051] Multi-Specific Antigen Binding Molecule: As used herein, the term “multispecific antigen binding molecule” refers to a molecule that comprises two or more antigenspecific binding sites. In some embodiments, a multi- specific antigen binding molecule is a multi- specific antibody (e.g., a bispecific antibody).

[0052] Multi- Specific Antibody: As used herein, the term “multi- specific antibody” refers to an antibody that comprises at least two distinct antigen- specific binding sites or at least two linked (covalently or non-covalently) antibodies that, combined, comprise at least two distinct antigen- specific binding sites. In some embodiments, a multi- specific antibody is a bispecific antibody. Non-limiting examples of multi- specific specific antibody formats or architectures are provided in Sawant MS, et al., Toward Drug-Like MultispecificAntibodies by Design, Int J Mol Sci. 2020 Oct 12;21(20):7496; Klein C, et al., The use of CrossMAb technology for the generation of bi- and multispecific antibodies, MAbs 2016 Aug-Sep;8(6): 1010-20; and Brinkmann U and Kontermann EE, The making of bispecific antibodies, MAbs. 2017 Feb / Mar;9(2): 182-212, the entire contents of each of which are incorporated herein by reference in their entireties.

[0053] Recombinant antibody: As used herein, the term "recombinant antibody", as used herein, is intended to include all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), including, for example, antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128- 145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. In some embodiments, recombinant human antibodies are provided herein. In certain embodiments, such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo. One embodiment of the disclosure provides fully human antibodies, e.g., capable of binding human KLK5 or KLK7, which can be generated using appropriate techniques, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et al., PCT publication No. WO 2005 / 007699 A2.

[0054] Selective: As used herein, the term “selective” or “selectively” refers to the ability of a molecule to produce an effect (e.g., inhibit, antagonize, agonize, etc.) in relation to its target molecule compared to a reference molecule. For example, a molecule that selectively inhibits its target molecule means that this molecule is capable of inhibiting itstarget molecule to a degree that is distinguishable from a reference molecule in an inhibition assay or other inhibitory context. For example, with respect to an inhibitor, the term, “selectively inhibits”, refers to the ability of the inhibitor to inhibit its target molecule with a degree that is distinguishable from a reference molecule that is not substantially inhibited in an inhibition assay, e.g., to an extent that permit selective inhibition of the target molecule, as described herein. Once the reaction is terminated, the signal produced by inhibiting the target molecule can be measured. The half maximal inhibitor concentration for the target molecule and the reference molecule can be calculated.

[0055] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds”, refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, which enables the antibody to be used to distinguish the specific antigen from others, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a KD for binding the target of at least about 10'4M, 10'5M, 10'6M, 10'7M, 10'8M, 10'9M, IO0M, 101M, 1042M, 1043M, or less. In some embodiments, an antibody specifically binds KLK5 or KLK7. In some embodiments, an antibody specifically binds a Th2 cytokine (e.g., IL- 13). In some embodiments, a bispecific antibody provided herein specifically binds KLK5 and KLK7 on one arm, and a Th2 cytokine or a receptor thereof (e.g., IL-13 or IL-13R) on another arm.

[0056] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, e.g., a human patient that has or is suspected of having a disease.

[0057] Th2 targeting antibody: As used herein, the term “Th2 targeting antibody” refers to an antibody that binds to a Th2 cytokine or a receptor thereof. In some embodiments, a Th2 targeting antibody inhibits Th2 cytokine mediated signaling. In some embodiments, a Th2 targeting antibody suppresses Th2 cytokine mediated inflammation.

[0058] Treatment: As used herein, the term “treating” or “treatment” refers to the application or administration of a composition including one or more active agents e.g., anti- KLK5 / KLK7 + IL- 13 bispecific antibodies) to a subject, who has a target disease or disorder, a symptom of the disease / disorder, or a predisposition toward the disease / disorder, with thepurpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder. Alleviating a target disease / disorder includes delaying or preventing the development or progression of the disease, or reducing disease severity. It will be understood that references to treating or treatment may also refer to antibodies, including KLK5 / KLK7 + IL- 13 bispecific antibodies for use in such methods.II. Antibodies(a) Dual inhibitor KLK5 and KLK7 Antibodies

[0059] In some embodiments, a dual inhibitor antibody targeting KLK5 and KLK7 (referred to as an anti-KLK5 / KLK7 antibody) is an antibody specific for both Kallikrein-5 (KLK5) and KLK7 via a common, specific antigen binding site. Dual inhibitor KLK5 / KLK7 antibodies are described in PCT / US2024 / 019231, the entire contents of which is incorporated herein by reference. Provided herein, in some aspects, are antibodies that bind to KLK5 (e.g., human KLK5, or mouse KLK5) and KLK7 (e.g., human KLK7, or mouse KLK7) with high specificity and affinity via a common antigen binding site. In some embodiments, the anti- KLK5 / KLK7 antibody described herein specifically binds to an epitope of KLK5 that is exposed or becomes exposed to an antibody, and an epitope of KLK7 that is exposed or becomes exposed to an antibody. In some embodiments, an anti-KLK5 / KLK7 antibody described herein binds to the active site of KLK5 and KLK7. In some embodiments, anti- KLK5 / KLK7 antibodies provided herein bind specifically to KLK5 and KLK7 from human, non-human primates, mouse, rat, etc. In some embodiments, anti-KLK5 / KLK7 antibodies provided herein specifically bind to human KLK5. In some embodiments, anti-KLK5 / LKL7 antibodies provided herein specifically bind to mouse KLK5. In some embodiments, anti- KLK5 / KLK7 antibodies provided herein specifically bind to human KLK7. In some embodiments, anti-KLK5 / LKL7 antibodies provided herein specifically bind to mouse KLK7. In some embodiments, multispecific antibodies are provided herein comprising an arm having an antigen- specific binding site of a dual inhibitor antibody targeting KLK5 and KLK7 and an arm having an antigen- specific binding site that specifically binds to IL- 13 or receptor thereof. For example, in some embodiments, bispecific antibodies are provided herein comprising an arm having an antigen- specific binding site of a dual inhibitor antibody targeting KLK5 and KLK and an arm having an antigen- specific binding site that specifically binds to IL- 13 or IL-13R.

[0060] In some embodiments, an anti-KLK5 / KLK7 antibody is not a bispecific antibody or bispecific antigen binding molecule in which KLK5 binding is conferred by one binding site within the antibody and KLK7 binding conferred by another binding site within the antibody.

[0061] In some embodiments, an anti-KLK5 / KLK7 antibody described herein may be characterized by reference to certain functional properties. In some embodiments, an anti- KLK5 / KLK7 antibody described herein binds specifically to KLK5 and KLK7. In some embodiments, an anti-KLK5 / KLK7 antibody binds specifically to the active form of KLK5 and KLK7. In some embodiments, an anti-KLK5 / KLK7 antibody does not bind the inactive form (the pro-form) of KLK5 and KLK7. In some embodiments, the antibody specifically binds to the active form of KLK5 and the active form of KLK7, but does not specifically bind the inactive form of KLK5 or the inactive form of KLK7. In some embodiments, the antibody detectably binds to the active form of KLK5 and the active form of KLK7, but under the same or comparable conditions does not detectably bind to the inactive form of KLK5 or the inactive form of KLK7. In some embodiments, an anti-KLK5 / KLK7 antibody inhibits KLK5 and KLK7 protease activity. In some embodiments, an anti-KLK5 / KLK7 antibody is not cleaved by KLK5 or KLK7 when bound to KLK5 or KLK7. In some embodiments, an anti- KLK5 / KLK7 antibody competes with SPINK5 and / or leupeptin for binding of the active site of KLK5 and KLK7. In some embodiments, an anti-KLK5 / KLK7 antibody reduces hyperkeratosis and desquamation. In some embodiments, an anti-KLK5 / KLK7 antibody reduces stratum corneum thickness. In some embodiments, an anti-KLK5 / KLK7 antibody reduces inflammation and epidermal effects.

[0062] Kallikrein-5, also known as stratum corneum tryptic enzyme (SCTE), is a serine protease expressed in the epidermis encoded by the KLK5 gene. The KLK5 gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome. Its expression is up-regulated by estrogens and progestins. KLK5 is expressed in the stratum granulosum and stratum corneum. In some embodiments, KLK5 regulates epidermal desquamation. In some embodiments, KLK5 regulates epidermal desquamation in conjunction with another member of the Kallikrein family proteases (e.g., KLK7 and / or KLK14). In some embodiments, KLK5 degrades proteins which form the epidermis (e.g., stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, or stratum basale). In some embodiments, KLK5 degrades proteins which form the stratum corneum and / or stratum granulosum (e.g., Corneodesmosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1 (DSC1), etc.). In the epidermis (e.g., stratum granulosum and stratumcomeum) KLK5 is expressed in an inactive form (sometimes referred to as the proform or pro-form), proKLK5, and can autoactivate itself. When activated, KLK5 can, through a proteolytic cleavage, convert both proKLK7 and proKLK14 to active forms. Active KLK14 is then able to activate newly produced proKLK5, thus creating a positive feedback loop (see, e.g., Nauroy et al., Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease, Matrix Biol Plus. 2019;6- 7:100019). KLK7 and KLK14 also degrade proteins which form the stratum corneum and / or stratum granulosum (e.g., Corneodesmosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1 (DSC1), etc.). Structural proteins, such as CDSN, DSG1, DSC1, are adhesive proteins of the extracellular part of the corneodesmosomes, the junctional structures that mediate comeocyte cohesion. The degradation of these proteins at the epidermis surface leads to desquamation, which may lead to skin barrier defects (e.g., stratum corneum detachment, decreased permeability barrier, allergy and inflammation, etc.). KLK5 and KLK7 have been implicated in this process (see, e.g., Caubet et al., Degradation of Comeodesmosome Proteins by Two Serine Proteases of the Kallikrein Family, SCTE / KLK5 / hK5 and SCCE / KLK7 / hK7, Journal of Investigative Dermatology, Volume 122, Issue 5, May 2004, Pages 1235-1244). Inhibition of KLK5 and / or KLK7 promotes improved skin barrier integrity and reduced inflammation (e.g., Chavarria-Smith et al., Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis, SCIENCE TRANSLATIONAL MEDICINE, 14 Dec 2022, Vol 14, Issue 675).

[0063] Kallikrein-7 is a serine protease that in humans is encoded by the KLK7 gene. KLK7 is characterized as stratum corneum chymotryptic enzyme (SCCE). [It is the seventh member of the human kallikrein family, which includes fifteen homologous serine proteases located on chromosome 19. KLK7 is secreted as an inactive zymogen (e.g., in the stratum granulosum layer of the epidermis), requiring proteolytic cleavage to be activated. In some embodiments, KLK5 or matriptase activates KLK7. Once active, KLK7 is able to cleave proteins which form the stratum comeum and / or stratum granulosum (e.g., Corneodesmosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1 (DSC1), etc.) (see, e.g., Caubet et al. (May 2004). Degradation of comeodesmosome proteins by two serine proteases of the kallikrein family, SCTE / KLK5 / hK5 and SCCE / KLK7 / hK7. The Journal of Investigative Dermatology. 122 (5): 1235-1244). These proteins constitute the extracellular component of corneodesmosomes, intercellular cohesive stmctures which link the intermediate filaments of adjacent cells in the stratum comeum. In some embodiments, proteolysis of corneodesmosomes leads to desquamation of the epidermis (i.e., the shedding of comeocytesfrom the outer layer of the epidermis). In some embodiments, the combined role of KLK5 and KLK7 suggests that KLK skin cascade is responsible for coordinating desquamation. KLK7 is a chymotrypsin-like serine protease, which cleaves proteins at the residues tyrosine, phenylalanine or leucine. In some embodiments, dysregulation of KLK7 has been linked to several skin disorders including atopic dermatitis, psoriasis and Netherton syndrome. These diseases are characterized by excessively dry, scaly and inflamed skin, due to a disruption of skin homeostasis and correct barrier function.

[0064] In some embodiments, an anti-KLK5 / KLK7 antibody described herein specifically binds to an epitope on human KLK5. Exemplary amino acid sequences of human KLK5 are set forth in NCBI Accession Numbers NP_001070959.1, NP_001070960.1, or NP_036559.1, and UniProt Accession Numbers: Q8IU55, Q6S9W8, M0QXX2, Q9P0G3, A0A2I2MP48, or A0A2I2MP49, the entire sequences of which are incorporated herein by reference.

[0065] In some embodiments, an anti-KLK5 / KLK7 antibody described herein specifically binds to an epitope on mouse KLK5. Exemplary amino acid sequences of mouse KLK5 are set forth in NCBI Accession Numbers NP_081082.1, XP_006541213.1,XP_006541214.1, XP_006541215.1, XP_036009294.1, or XP_036009295.1, and UniProtAccession Numbers P15945, or Q9D140, the entire sequences of which are incorporated herein by reference.

[0066] In some embodiments, an anti-KLK5 / KLK7 antibody described herein specifically binds to an epitope on human KLK7 via the same antigen binding site that binds to KLK5 (e.g., human KLK5 or mouse KLK5). Exemplary amino acid sequences of human KLK7 are set forth in NCBI Accession Numbers NP_001193982.1, NP_001230055.1, NP_005037.1, NP_644806.1, and UniProt Accession Numbers: M0QYU8, Q6DTY1, X2J289, X2J4X7, A0A024R4H6, P49862, A0A2H4GDB2, and A0A2H4GDB6, the entire sequences of which are incorporated herein by reference.

[0067] In some embodiments, an anti-KLK5 / KLK7 antibody described herein specifically binds to an epitope on mouse KLK7 via the same antigen binding site that binds to KLK5 (e.g., human KLK5 or mouse KLK5). Exemplary amino acid sequences of mouse KLK7 are set forth in NCBI Accession Numbers NP_036002.1, and UniProt Accession Numbers Q91VE3, the entire sequences of which are incorporated herein by reference.

[0068] In some embodiments, an anti-KLK5 / KLK7 antibody described herein specifically binds to an epitope on KLK5 (e.g., active site of the enzyme, also known as the catalytic domain / pocket of human KLK5 or mouse KLK5) and an epitope on KLK7 (e.g., thecatalytic domain / pocket of human KLK7 or mouse KLK7). In some embodiments, an anti- KLK5 / KLK7 antibody described herein prevents KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) from cleaving its substrates. In some embodiments, an anti-KLK5 antibody described herein binds to a fragment of KLK5 (e.g., human or mouse KLK5) and a fragment of KLK7 (e.g., human or mouse KLK7). The fragment of KLK5 and / or KLK7 (e.g., human or mouse) may be between about 5 and about 425 amino acids, between about 10 and about 400 amino acids, between about 50 and about 350 amino acids, between about 100 and about 300 amino acids, between about 150 and about 250 amino acids, between about 200 and about 300 amino acids, between about 75 and about 150 amino acids, between about 25 and about 100 amino acids, between about 10 and about 30 amino acids in length. Not wishing to be bound to any particular theory, and in some embodiments, a heavy chain (HC) complementarity-determining region 3 (CDR3) of any one of the anti- KLK5 / KLK7 antibodies described herein inhibits KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) by binding to the catalytic domain / pocket of KLK5.

[0069] In some embodiments, an anti-KLK5 / KLK7 antibody described herein inhibits KLK5 protease activity, KLK7 protease activity, or both KLK5 and KLK7 protease activity. In some embodiments the anti-KLK5 / KLK7 antibody inhibits KLK5 cleavage of BOC-Val- Pro-Arg-AMC with an IC50 of less than 30nM, less than 25 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 3 nM, less than 2.5 nM, less than 2 nM, or less than 1.5 nM, less than InM, less than 0.5nM, less than 0.3nM, less than 0.25nM, less than 0.2 nM or less than 0.1 nM. In some embodiments, the anti-KLK5 / KLK7 antibody inhibits KLK5 (e.g., human KLK5 or mouse KLK5) cleavage of BOC-Val-Pro-Arg-AMC with an IC50 in the range of 0.1 nM to 30 nM, 0.1 nM to 20 nM, 0.1 nM to 10 nM, 0.1 nM to 5 nM, 0.1 nM to 2.5 nM, 0.1 nM to 2 nM, 0.1 nM to 1 nM, 0.1 nM to 0.5 nM, 0.1 nM to 0.25 nM, 0.1 nM to 50 nM, 0.1 nM to 40 nM, 0.1 nM to 30 nM, 0.1 nM to 20 nM, 0.1 nM to 10 nM, 0.1 nM to 5 nM, 0.1 nM to 2.5 nM, 0.1 nM to 2 nM, 0.1 nM to 1 nM, 0.1 nM to 0.9 nM, 0.1 nM to 0.8 nM, 0.1 nM to 0.7 nM, 0.1 nM to 0.6 nM, 0.1 nM to 0.5 nM, 0.1 nM to 0.4 nM, 0.1 nM to 0.3 nM, 0.1 nM to 0.25 nM, 0.1 nM to 0.2 nM, 0.1 nM to 0.15 nM, 0.15 nM to 0.2 nM, 0.15 nM to 0.25 nM, 0.15 nM to 0.3 nM, 0.15 nM to 0.4 nM, 0.15 nM to 0.5 nM, 0.15 nM to 1 nM, 0.2 nM to 30 nM, 0.2 nM to 20 nM, 0.2 nM to 10 nM, 0.2 nM to 5 nM, 0.2 nM to 2.5 nM, 0.2 nM to 2 nM, 0.2 nM to 1 nM, 0.2 nM to 0.5 nM, 0.2 nM to 0.2 nM, 0.2 nM to 50 nM, 0.2 nM to 40 nM, 0.2 nM to 30 nM, 0.2 nM to 20 nM, 0.2 nM to 10 nM, 0.2 nM to 5 nM, 0.2 nM to 2.5 nM, 0.2 nM to 2 nM, 0.2 nM to 1 nM, 0.2 nM to 0.9 nM, 0.2 nM to 0.8 nM, 0.2 nM to 0.7 nM, 0.2 nM to 0.6 nM, 0.2 nM to 0.5 nM, 0.2 nM to 0.4 nM, 0.2 nM to 0.3nM, 0.2 nM to 0.25 nM, 1 nM to 30 nM, 1 nM to 20 nM, 1 nM to 10 nM, 1 nM to 5 nM, 1 nM to 2.5 nM, 1 nM to 2 nM, 1 nM to 3 nM, 1 nM to 5.5 nM, 1.5 nM to 2 nM, 1.5 nM to 3 nM, 1.5 nM to 5.5 nM, 2 nM to 5 nM, 2 nM to 4 nM, 2 nM to 5.5 nM, 3 nM to 5.5 nM, 4 nM to 5.5 nM, 3 nM to 30 nM, 3 nM to 20 nM, 3 nM to 10 nM, 3 nM to 5 nM, 3 nM to 2.5 nM, 3 nM to 4 nM, 3 nM to 5.5 nM, 5 nM to 30 nM, 5 nM to 20 nM, 5 nM to 10 nM, 5 nM to 9 nM, 5 nM to 8 nM, 5 nM to 7 nM, 5 nM to 6 nM, 5 nM to 5.5 nM, 10 nM to 30 nM, 10 nM to 25 nM, 10 nM to 20 nM, 10 nM to 18 nM, 10 nM to 15 nM, 10 nM to 12 nM, 12 nM to 20 nM, 12 nM to 25 nM, 12 nM to 16 nM, 12 nM to 18 nM, 12 nM to 20 nM, 12 nM to 24 nM, 12 nM to 28 nM, 12 nM to 30 nM, 15 nM to 30 nM, 15 nM to 25 nM, 15 nM to 20 nM, 15 nM to 18 nM, 18 nM to 30 nM, 18 nM to 25 nM, 18 nM to 20 nM, 20 nM to 30 nM, 20 nM to 25 nM, 20 nM to 22 nM, 20 nM to 24 nM, 20 nM to 26 nM, 20 nM to 28 nM, 22 nM to 30 nM, 22 nM to 25 nM, 22 nM to 28 nM, 24 nM to 30 nM, 24 nM to 25 nM, 24 nM to 26 nM, or 24 nM to 28 nM. In some embodiments the anti-KLK5 / KLK7 antibody inhibits KLK7 cleavage of KHLF-AMC with an IC50 of less than 6 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2.5 nM, less than 2 nM, or less than 1.5 nM, less than 1 nM, less than 0.5 nM, less than 0.4nM, less than 0.3nM, less than 0.2nM, less than 0.16 nM, less than 0.1 nM or less than 0.05 nM. In some embodiments the anti-KLK5 / KLK7 antibody inhibits KLK7 cleavage of KHLF-AMC with an IC50 in the range of 0.1 nM to 30 nM, 0.1 nM to 20 nM, 0.1 nM to 10 nM, 0.1 nM to 5 nM, 0.1 nM to 2.5 nM, 0.1 nM to 2 nM, 0.1 nM to 1 nM, 0.1 nM to 0.5 nM, 0.1 nM to 0.25 nM, 0.1 nM to 50 nM, 0.1 nM to 40 nM, 0.1 nM to 30 nM, 0.1 nM to 20 nM, 0.1 nM to 10 nM, 0.1 nM to 5 nM, 0.1 nM to 2.5 nM, 0.1 nM to 2 nM, 0.1 nM to 1 nM, 0.1 nM to 0.9 nM, 0.1 nM to 0.8 nM, 0.1 nM to 0.7 nM, 0.1 nM to 0.6 nM, 0.1 nM to 0.5 nM, 0.1 nM to 0.4 nM, 0.1 nM to 0.3 nM, 0.1 nM to 0.25 nM, 0.1 nM to 0.2 nM, 0.1 nM to 0.15 nM, 0.15 nM to 0.2 nM, 0.15 nM to 0.25 nM, 0.15 nM to 0.3 nM, 0.15 nM to 0.4 nM, 0.15 nM to 0.5 nM, 0.15 nM to 1 nM, 0.2 nM to 30 nM, 0.2 nM to 20 nM, 0.2 nM to 10 nM, 0.2 nM to 5 nM, 0.2 nM to 2.5 nM, 0.2 nM to 2 nM, 0.2 nM to 1 nM, 0.2 nM to 0.5 nM, 0.2 nM to 0.2 nM, 0.2 nM to 50 nM, 0.2 nM to 40 nM, 0.2 nM to 30 nM, 0.2 nM to 20 nM, 0.2 nM to 10 nM, 0.2 nM to 5 nM, 0.2 nM to 2.5 nM, 0.2 nM to 2 nM, 0.2 nM to 1 nM, 0.2 nM to 0.9 nM, 0.2 nM to 0.8 nM, 0.2 nM to 0.7 nM, 0.2 nM to 0.6 nM, 0.2 nM to 0.5 nM, 0.2 nM to 0.4 nM, 0.2 nM to 0.3 nM, 0.2 nM to 0.25 nM, 1 nM to 30 nM, 1 nM to 20 nM, 1 nM to 10 nM, 1 nM to 5 nM, 1 nM to 2.5 nM, 1 nM to 2 nM, 1 nM to 3 nM, 1 nM to 5.5 nM, 1.5 nM to 2 nM, 1.5 nM to 3 nM, 1.5 nM to 5.5 nM, 2 nM to 5 nM, 2 nM to 4 nM, 2 nM to 5.5 nM, 3 nM to 5.5 nM, 4 nM to 5.5 nM, 3 nM to 30 nM, 3 nM to 20 nM, 3 nM to 10 nM, 3 nM to 5 nM, 3 nM to 2.5 nM, 3 nM to 4 nM, 3 nM to 5.5 nM, 5 nM to 30 nM, 5 nM to 20 nM, 5nM to 10 nM, 5 nM to 9 nM, 5 nM to 8 nM, 5 nM to 7 nM, 5 nM to 6 nM, 5 nM to 5.5 nM, 10 nM to 30 nM, 10 nM to 25 nM, 10 nM to 20 nM, 10 nM to 18 nM, 10 nM to 15 nM, 10 nM to 12 nM, 12 nM to 20 nM, 12 nM to 25 nM, 12 nM to 16 nM, 12 nM to 18 nM, 12 nM to 20 nM, 12 nM to 24 nM, 12 nM to 28 nM, 12 nM to 30 nM, 15 nM to 30 nM, 15 nM to 25 nM, 15 nM to 20 nM, 15 nM to 18 nM, 18 nM to 30 nM, 18 nM to 25 nM, 18 nM to 20 nM, 20 nM to 30 nM, 20 nM to 25 nM, 20 nM to 22 nM, 20 nM to 24 nM, 20 nM to 26 nM, 20 nM to 28 nM, 22 nM to 30 nM, 22 nM to 25 nM, 22 nM to 28 nM, 24 nM to 30 nM, 24 nM to 25 nM, 24 nM to 26 nM, or 24 nM to 28 nM.

[0070] In some embodiments, an anti-KLK5 / KLK7 antibody described herein binds specifically to the active form of KLK5, KLK7 or KLK5 and KLK7. In some embodiments, the anti-KLK5 / KLK7 antibody described herein does not bind to the inactive form of KLK5, KLK7, or KLK5 and KLK7. In some embodiments, an anti-KLK5 / KLK7 antibody described herein binds specifically to the active site of KLK5, KLK7 or KLK5 and KLK7. In some embodiments, the anti-KLK5 / KLK7 antibody described herein specifically binds to the active form of KLK5, the active form of KLK7, or the active form of KLK5 and the active form of KLK7, but does not specifically bind to the inactive form of KLK5, the inactive form of KLK7, or the inactive form of KLK5 and the inactive form of KLK7. In some embodiments, the anti-KLK5 / KLK7 antibody described herein detectably binds the active form of KLK5, the active form of KLK7, or the active form of KLK5 and the active form of KLK7, but under the same or comparable conditions does not detectably bind the inactive form of KLK5, the inactive form of KLK7, or the inactive form of KLK5 and the inactive form of KLK7. The active site of KLK5 and / or KLK7 is the site at which the KLK5 and / or KLK7 substrate molecules bind to undergo cleavage. The active site may also be known as the catalytic domain, or catalytic triad. In some embodiments, the active site (i.e., catalytic domain or catalytic triad) of KLK5 or KLK7 consists of amino acids Serl95, His57, and Asp 102 of KLK5 or KLK7 (see, e.g., Goettig et al., Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs), Biochimie. 2010 Nov; 92(11): 1546-1567).

[0071] In some embodiments, antibodies described herein are optimized versions (e.g., affinity matured) of the parental antibody. In some embodiments, an antibody described herein specifically binds a KLK5 (e.g., a human or mouse KLK5) and a KLK7 (e.g., a human or mouse KLK7) with binding affinity (e.g., as indicated by KD) of at least about IO"4M, at least about 10'5M, at least about 10'6M, at least about 10'7M, at least about 10'8M, at least about 10'9M, at least about 1040M, at least about 101M, at least about 102M, at least about 1043M, or less. In some embodiments, an antibody described herein specifically bindsa KLK5 (e.g., a human or mouse KLK5) ) and a KLK7 (e.g., a human or mouse KLK7) with binding affinity (e.g., as indicated by KD) of between IxlO'10M and 5xl0'9M, between 1x10’10M and 1X10'9M, between 5xlO'10and IxlO'9M, between 5xl0'nand IxlO'10M, between IxlO'11and 5xlO'10M, or between 5xl0'13and IxlO'12M. For example, an antibody of the present disclosure can bind to a KLK5 protein (e.g., human or mouse KLK5) ) and a KLK7 (e.g., a human or mouse KLK7) with an affinity between 1 pM and 500 nM, e.g., between 50 pM and 100 nM, between 500 pM and 50 nM, between 1 pM and 100 pM, between 10 pM and 100 pM, between 50 pM and 100 pM, between 100 pM and 500 pM, between 500 pM and 1 nM, between 1 nM and 5 nM, between 1 nM and 10 nM, between 5 nM and 25 nM, between 10 nM and 50 nM between 50 nM and 100 nM, between 100 nM and 500 nM. The disclosure also includes antibodies that compete with any of the antibodies described herein for binding to a KLK5 protein (e.g., human or mouse KLK5) ) and a KLK7 (e.g., a human or mouse KLK7) and that have an affinity of 100 nM or lower (e.g., 80 nM or lower, 50 nM or lower, 20 nM or lower, 10 nM or lower, 1 nM or lower, 500 pM or lower, 50 pM or lower, or 5 pM or lower). The affinity and binding kinetics of an antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, antibodies described herein bind to KLK5 and KLK7 with a KD of sub-nanomolar range.

[0072] Binding affinity (or binding specificity) can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance (SPR), florescent activated cell sorting (FACS) or spectroscopy (e.g., using a fluorescence assay). Exemplary conditions for evaluating binding affinity are in HBS- P buffer (10 mM HEPES pH7.4, 150 mM NaCl, 0.005% (v / v) surfactant P20) and PBS buffer (lOmM PO4-3, 137mM NaCl, and 2.7mM KC1). These techniques can be used to measure the concentration of bound proteins as a function of target protein concentration. The concentration of bound protein ([[Bound]]) is generally related to the concentration of free target protein ([[Free]]) by the following equation:[[Bound]] = [[Free]] / (Kd+[[Free]])

[0073] It is not always necessary to make an exact determination of KA, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to KA, and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay.Exemplary anti-KLK5 / KLK7 antibody sequences (e.g., the heavy chain (HC) and light chain (LC) sequences, heavy chain variable domain (VH) and light chain variable domain (VL), CDR sequences are provided in Tables la and lb.Table la. Examples of anti-KLK5 / KLK7 antibodies

[0074] In some embodiments, certain amino acid positions in an antibody describedherein (e.g., amino acids in the VH / VL regions and / or CDR regions) are substitutable and the substitution results in an antibody with substantially similar binding and biological activities (e.g., substantially similar binding affinity, binding specificity, protease activity inhibitory activity, anti-inflammatory activity, or a combination thereof) as the reference antibody. In order to identify a substitutable position of an antibody, the amino acid sequence of that antibody is compared to the sequences of other antibodies belonging to the same group as that antibody. If the identity of that amino acid varies between the different related antibodies of a group at any particular position, that position is a substitutable position of the antibody. In other words, a substitutable position is a position in which the identity of the amino acid varies between the related antibodies. Positions that contain a constant amino acid are not substitutable positions.

[0075] In some embodiments, the above method may be employed to provide a consensus antibody sequence. In such a consensus sequence, a non-substitutable position is indicated by the amino acid present at that position, and a substitutable position is indicated as an "X".

[0076] Depending on how the antibodies are to be employed, X may be a) any amino acid, b) any amino acid present at that position in any of the related antibodies in the group or a conservatively substituted variant thereof or c) any amino acid present at that position in any of the related antibodies in the group. Any antibody having a sequence that is encompassed by the consensus should bind to the same antigen as any of the related antibodies.

[0077] In some embodiments, the method described above may be employed in methods of designing and making a variant of a parental antibody that at least maintains (e.g., maintains or increases) the antigen binding activity of the parental antibody. Because antibodies containing substitutions at substitutable positions have already been produced and tested, substitutions at those positions can be made in the knowledge that they should not significantly decrease the binding activity of the antibody. In general, an antibody variant of a parental antibody has an antigen binding affinity that is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% (e.g., at least 150%, at least 200%, at least 500%, at least 1000%, usually up to at least 10,000%) of the binding affinity of the parental antibody to a particular antigen.

[0078] In some embodiments, a substitutable position of a parental antibody may be substituted by a) any of the 20 naturally occurring amino acids to produce random substitutions, b) an amino acid having biochemical properties similar to the amino acidalready present at the substitutable position to produce conservative substitutions, c) an amino acid that is present at the same position in a related antibody to produce a directed substitution, or d) an amino acid that is present at the same position in a similar human antibody to produce a humanizing substitution. A substitution may be made at any part of an antibody variable region, including any framework region or CDR. In certain embodiments, a single substitutable amino acid may be substituted. However, in other embodiments, a plurality of substitutable amino acids (e.g., up to about 5 or 10 or more) may be substituted. In particular embodiments, the type of substitution that can be made at each substitutable position may be indicated by the types of amino acids present at that position in the related antibodies. For example, if unrelated amino acids (e.g., Ala, Gly, Cys, Glu and Thr) are present at a certain position of a group of related antibodies, then any amino acid could be substituted at that position without significantly reducing binding activity of the antibody. Exemplary amino acids substitutions of an anti-KLK5 / KLK7 antibody described herein are set forth in Table lb:Table lb. Exemplary Anti-KLK5 / KLK7 Antibody Amino Acid Substitutions

[0079] In some embodiments, an antibody of the present disclosure comprises a HC CDR1 comprising the amino acid sequence of GSISSX1DYYWX2 (SEQ ID NO: 28), in which Xi is S, D or L., X2 is G or V; a HC CDR2 comprising the amino acid sequence of SIX3YX4X5X6TYYX7PSLKS (SEQ ID NO: 29), in which X3is Y or D, X4is S, F or Y, X5isG or A, Xe is S or D, or X7 is N or S; a HC CDR3 comprising the amino acid sequence of ARGRPLGYGAX8HX9YYGMDV (SEQ ID NO: 30), in which X8is R or K, or X9is Y or D; a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4; a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5; and / or a LC CDR3 comprising the amino acid sequence of QQSPX10FPPLT (SEQ ID NO: 31), in which X10 is P or Y.

[0080] In some embodiments, an antibody of the present disclosure comprises one or more of the HC CDRs (e.g., HC CDR1, HC CDR2, or HC CDR3) amino acid sequences from any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, an antibody of the present disclosure comprises the HC CDR3 amino acid sequences from any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, an antibody of the present disclosure comprises the HC CDR1, HC CDR2, and HC CDR3 as provided for any one of the antibodies elected from Tables la and lb. In some embodiments, an antibody of the present disclosure comprises the LC CDR3 amino acid sequences from any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, an antibody of the present disclosure comprises one or more of the LC CDRs (e.g., LC CDR1, LC CDR2, or LC CDR3) amino acid sequences from any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, an antibody of the present disclosure comprises the LC CDR1, LC CDR2, and LC CDR3 s provided for any one of the anti-KLK5 antibodies selected from Tables la and lb.

[0081] In some embodiments, an antibody of the present disclosure comprises the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 as provided for any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, antibody heavy and / or light chain CDR3 domains may play a particularly important role in the binding specificity / affinity of an antibody for an antigen. Accordingly, an antibody of the disclosure may include at least the heavy and / or light chain CDR3s of any one of the anti- KLK5 / KLK7 antibodies selected from Tables la and lb.

[0082] Also within the scope of the present disclosure are variants of any of the exemplary anti-KLK5 / KLK7 antibodies as disclosed herein. A variant may contain one or more amino acid residue variations in the VH and / or VL, or in one or more of the HC CDRs and / or one or more of the LC CDRs as relative to the reference antibody, while retaining substantially similar binding and biological activities (e.g., substantially similar binding affinity, binding specificity, protease activity inhibitory activity, anti-inflammatory activity, or a combination thereof) as the reference antibody.

[0083] In some embodiments, an antibody of the disclosure has one or more CDRs (e.g., HC CDR or LC CDR) sequences substantially similar to any of the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 sequences from one of the anti- KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, the position of one or more CDRs along the VH (e.g., HC CDR1, HC CDR2, or HC CDR3) and / or VL (e.g., LC CDR1, LC CDR2, or LC CDR3) region of an antibody described herein can vary by one, two, three, four, five, or six amino acid positions so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived). For example, in some embodiments, the position defining a CDR of any antibody described herein can vary by shifting the N-terminal and / or C-terminal boundary of the CDR by one, two, three, four, five, or six amino acids, relative to the CDR position of any one of the antibodies described herein, so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived). In another embodiment, the length of one or more CDRs along the VH (e.g., HC CDR1, HC CDR2, or HC CDR3) and / or VL (e.g., LC CDR1, LC CDR2, or LC CDR3) region of an antibody described herein can vary (e.g., be shorter or longer) by one, two, three, four, five, or more amino acids, so long as immuno specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the binding of the original antibody from which it is derived).

[0084] Accordingly, in some embodiments, a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein may be one, two, three, four, five or more amino acids shorter than one or more of the CDRs described herein (e.g., CDRS from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein may be one, two, three, four, five or more amino acids longer than one or more of the CDRs described herein (e.g., CDRs fromany of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the amino portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be extended by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRs from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the carboxy portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be extended by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRs from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the amino portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be shortened by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRs from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, the carboxy portion of a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 described herein can be shortened by one, two, three, four, five or more amino acids compared to one or more of the CDRs described herein (e.g., CDRs from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibodyfrom which it is derived). Any method can be used to ascertain whether specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained, for example, using binding assays and conditions described in the art.

[0085] In some examples, an antibody of the disclosure has one or more CDR (e.g., HC CDR or LC CDR) sequences substantially similar to any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. For example, an antibody described herein may include one or more CDR sequence(s) from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb containing up to 5, 4, 3, 2, or 1 amino acid residue variations as compared to the corresponding CDR region in any one of the CDRs provided herein (e.g., CDRs from any of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb) so long as specific binding to KLK5 (e.g., human or mouse KLK5) and KLK7 (e.g., human or mouse KLK7) is maintained (e.g., substantially maintained, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% relative to the binding of the original antibody from which it is derived). In some embodiments, any of the amino acid variations in any of the CDRs provided herein may be conservative variations. Conservative variations can be introduced into the CDRs at positions where the residues are not likely to be involved in interacting with a KLK5 (e.g., human or mouse KLK5) and / or a KLK7 (e.g., human or mouse KLK7), for example, as determined based on a crystal structure. Some aspects of the disclosure provide antibodies that comprise one or more of the heavy chain variable (VH) and / or light chain variable (VL) domains provided herein. In some embodiments, any of the VH domains provided herein include one or more of the HC CDR sequences (e.g., HC CDR1, HC CDR2, and HC CDR3) provided herein, for example, any of the HC CDR sequences provided in any one of the anti-KLK5 / KLK7 selected from Tables la and lb. In some embodiments, any of the VL domains provided herein include one or more of the LC CDR sequences (e.g., LC CDR1, LC CDR2, and LC CDR3) provided herein, for example, any of the LC CDR sequences provided in any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb.

[0086] In some embodiments, an antibody of the disclosure includes any antibody that includes a heavy chain variable domain and / or a light chain variable domain of any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb, and variants thereof. In some embodiments, an antibody of the disclosure includes any antibody that includes the heavy chain variable and light chain variable pairs of any anti-KLK5 / KLK7 antibodies selected from Tables la and lb.

[0087] Aspects of the disclosure provide antibodies having a heavy chain variable (VH) and / or a light chain variable (VL) domain amino acid sequence homologous to any of those described herein. In some embodiments, an antibody comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the heavy chain variable sequence and / or any light chain variable sequence of any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb. In some embodiments, the homologous heavy chain variable and / or a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) may occur within a heavy chain variable and / or a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, an antibody provided herein comprise a heavy chain variable sequence and a light chain variable sequence that comprises a framework sequence that is at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the framework sequence of any anti-KLK5 / KLK7 antibodies selected from Tables la and lb.

[0088] In some embodiments, an antibody of the present disclosure is a humanized antibody (e.g., a humanized variant containing one or more CDRs of Tables la and lb). In some embodiments, an antibody of the present disclosure comprises a HC CDR1, a HC CDR2, a HC CDR3, a LC CDR1, a LC CDR2, and a LC CDR3 that are the same as the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 shown in Tables la and lb, and comprises a humanized heavy chain variable region and / or a humanized light chain variable region.

[0089] In some embodiments, an antibody of the present disclosure is a humanized antibody comprising a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH of any of the anti-KLK5 / KLK7 antibodies listed in Tables la and lb. Alternatively or in addition, the antibody of the present disclosure is a humanized antibody comprising a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) ascompared with the VL of any one of the anti-KLK5 / KLK7 antibodies listed in Tables la and lb.

[0090] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 7. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 8.

[0091] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 1, a HC CDR2 having the amino acid sequence of SEQ ID NO: 2, a HC CDR3 having the amino acid sequence of SEQ ID NO: 3, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 6.

[0092] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 1, HC CDR2 having the amino acid sequence of SEQ ID NO: 2, and HC CDR3 having the amino acid sequence of SEQ ID NO: 3. “Collectively,” as used anywhere in the present disclosure, means that the total number of amino acid variations in all of the three heavy chain CDRs is within the defined range. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 6.

[0093] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 1, HC CDR2 having the amino acid sequence of SEQ ID NO: 2, and HC CDR3 having the amino acid sequence of SEQ ID NO: 3. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g.,at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 6.

[0094] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 1; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 2; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 3. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 5; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 6.

[0095] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 7. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 8.

[0096] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 7. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 8.

[0097] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 7. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 8.

[0098] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 13. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.

[0099] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 10, a HC CDR3 having the amino acid sequence of SEQ ID NO: 11, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000100] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 9, HC CDR2 having the amino acid sequence of SEQ ID NO: 10, and HC CDR3 having the amino acid sequence of SEQ ID NO: 11. “Collectively,” as used anywhere in the present disclosure, means that the total number of amino acid variations in all of the three heavy chain CDRs is within the defined range. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000101] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to theHC CDR1 having the amino acid sequence of SEQ ID NO: 9, HC CDR2 having the amino acid sequence of SEQ ID NO: 10, and HC CDR3 having the amino acid sequence of SEQ ID NO: 11. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000102] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 9; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 10; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 11. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 5; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000103] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 13. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 14.[000104] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 13. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a VL containing no more than 20amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 14.[000105] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 13. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 14.[000106] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 17. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.[000107] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 15, a HC CDR3 having the amino acid sequence of SEQ ID NO: 16, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000108] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 9, HC CDR2 having the amino acid sequence of SEQ ID NO: 15, and HC CDR3 having the amino acid sequence of SEQ ID NO: 16. “Collectively,” as used anywhere in the present disclosure, means that the total number of amino acid variations in all of the three heavy chain CDRs is within the defined range. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4,LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000109] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 9, HC CDR2 having the amino acid sequence of SEQ ID NO: 15, and HC CDR3 having the amino acid sequence of SEQ ID NO: 16. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000110] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 9; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 15; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 16. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 5; and / or a LC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000111] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 17. Alternatively or inaddition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 14.[000112] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 17. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 14.[000113] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 17. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 14.[000114] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 21. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.[000115] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 18, a HC CDR2 having the amino acid sequence of SEQ ID NO: 19, a HC CDR3 having the amino acid sequence of SEQ ID NO: 20, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000116] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 18, HC CDR2 having the amino acid sequence of SEQ ID NO: 19, and HC CDR3 having the amino acidsequence of SEQ ID NO: 20. “Collectively,” as used anywhere in the present disclosure, means that the total number of amino acid variations in all of the three heavy chain CDRs is within the defined range. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3, which collectively contains no more than 5 amino acid variations (e.g., no more than 5, 4, 3, 2 or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000117] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a HC CDR1, a HC CDR2, and a HC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the HC CDR1 having the amino acid sequence of SEQ ID NO: 18, HC CDR2 having the amino acid sequence of SEQ ID NO: 19, and HC CDR3 having the amino acid sequence of SEQ ID NO: 20. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a LC CDR1, a LC CDR2, and a LC CDR3 that collectively are at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the to the LC CDR1 having the amino acid sequence of SEQ ID NO: 4, LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000118] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises: a HC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR1 having the amino acid sequence of SEQ ID NO: 18; a HC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR2 having the amino acid sequence of SEQ ID NO: 19; and / or a HC CDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the HC CDR3 having the amino acid sequence of SEQ ID NO: 20. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises: a LC CDR1 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR1 having the amino acid sequence of SEQ ID NO: 4; a LC CDR2 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR2 having the amino acid sequence of SEQ ID NO: 5; and / or a LCCDR3 having no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000119] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 21. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 14.[000120] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 21. Alternatively or in addition, the anti- KLK5 / KLK7 antibody of the present disclosure comprises a VL containing no more than 20 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 14.[000121] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure comprises a VH comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH as set forth in SEQ ID NO: 21. Alternatively or in addition, the anti-KLK5 / KLK7 antibody of the present disclosure comprises a VL comprising an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL as set forth in SEQ ID NO: 14.[000122] The antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, F(ab'), F(ab')2, Fv), single chain antibodies, bispecific antibodies, or nanobodies. In some embodiments, the anti-KLK5 / KLK7 antibody described herein is a scFv. In some embodiments, the anti-KLK5 / KLK7 antibody described herein is a scFv-Fab (e.g., scFv fused to a portion of a constant region).[000123] In some embodiments, an anti-KLK5 / KLK7 antibody of the present disclosure is a chimeric antibody, which can include a heavy constant region and a light constant region from a human antibody. Chimeric antibodies refer to antibodies having a variable region or part of variable region from a first species and a constant region from a second species. Typically, in these chimeric antibodies, the variable region of both light and heavy chainsmimics the variable regions of antibodies derived from one species of mammals (e.g., a nonhuman mammal such as mouse, rabbit, and rat), while the constant portions are homologous to the sequences in antibodies derived from another mammal such as human. In some embodiments, amino acid modifications can be made in the variable region and / or the constant region.[000124] In some embodiments, an antibody of the present disclosure comprises a VL domain and / or VH domain of any one of the anti-KLK5 / KLK7 antibodies selected from Tables la and lb, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.[000125] In some embodiments, the light chain of any of the anti-KLK5 / KLK7 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain.[000126] Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IM GT database (www.imgt.org) or at www.vbase2.org / vbstat.php., both of which are incorporated by reference herein.[000127] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., human or mouse KLK5 and / or human or mouse KLK7), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Ec region of an anti-KLK5 / KLK7 antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or CH3 domain (residues 341-447 of human IgGl) and / or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Ec receptor binding and / or antigen-dependent cellular cytotoxicity.[000128] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Ec region (CHI domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased)as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CHI domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.[000129] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgGl) and / or CH3 domain (residues 341-447 of human IgGl) and / or the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631, which are incorporated herein by reference.[000130] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (e.g., decrease or increase) half-life of the antibody in vivo. See, e.g., International Publication Nos. WO 02 / 060919; WO 98 / 23289; and WO 97 / 34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (e.g., decrease or increase) the half-life of an antibody in vivo.[000131] In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn- binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-KLK5 / KLK7 antibody in vivo. In some embodiments, one, two or more amino acid mutations (i.e., substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody in vivo. In some embodiments, the antibodies can have one or more amino acid mutations (e.g., substitutions) in the second constant (CH2) domain (residues 231-340 of human IgGl) and / or the third constant (CH3) domain (residues 341-447 of human IgGl), with numbering according to the EU index inKabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgGl of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased halflife as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.[000132] In some embodiments, an antibody comprises an Fc region that has been engineered for half-life extension purposes, e.g., by introducing M428L and / or N434A substitutions. Non-limiting examples of such Fc variants affecting half-life in circulation are provided in Saunders KO, Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life, Front Immunol. 2019; 10: 1296, the contents of which are incorporated herein by reference.[000133] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti- KLK5 / KLK7 antibody, e.g., by introducing Leu234Ala and Leu235Ala mutations (commonly called LALA mutations). The effector ligand to which affinity is altered can be, for example, an Fc receptor or the Cl component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604). [000134] In some embodiments, one or more amino in the constant region of an anti- KLK5 / KLK7 antibody described herein can be replaced with a different amino acid residue such that the antibody has altered Clq binding and / or reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No.6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N- terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94 / 29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and / or to increase the affinity of the antibody for an Fey receptor. This approach is described further in International Publication No. WO 00 / 42072.[000135] In some embodiments, an antibody comprises an Fc variant comprising amino acid substitutions L234A, L235E, and P329G, wherein numbering is according to the EU index. In some embodiments, the antibody comprising the Fc variant exhibits reduced affinity to one or more or each of FcyRJ, FcyRIIA, FcyRIIIA, and Clq as compared to an antibody comprising the wild- type human Fc region. Examples of such Fc variants are provided in International Patent Application Publication No.: WO 2021 / 055669 entitled, FC VARIANTS WITH REDUCED EFFECTOR FUNCTION, published on March 25, 2021; and US Patent Application Publication No.: US 2021-0087271 entitled, FC VARIANTS WITH REDUCED EFFECTOR FUNCTION, published on March 25, 2021, the contents of which are incorporated herein by reference.[000136] In some embodiments, the heavy and / or light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR- grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind KLK5 and KLK7, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to KLK5 and KLK7 relative to the original antibody from which it is derived.[000137] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse / human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241Kabat numbering) is converted to proline resulting in an IgGl-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.[000138] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and / or methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C- glycosylation, glypiation (GPI anchor attachment), and / or phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N- acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g., a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “Modified antibody, antibody-conjugate and process for the preparation thereof’.[000139] In some embodiments, any one of the anti-KLK5 / KLK7 antibodies described herein may comprise a signal peptide in the heavy and / or light chain sequence (e.g., a N- terminal signal peptide). In some embodiments, the anti-KLK5 / KLK7 antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab') heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide).(b) IL-13 / IL-13R Targeting Antibodies[000140] Conditions associated with barrier dysfunction is characterized by barrier disruption and T helper 2 (Th2)-driven inflammation, e.g., inflammation mediated by Th2 cytokines and receptors thereof such as IL-13, IL-13 receptor (IL-13R), IL-4, IL-4R, IL-5,IL-5R, IL-6, IL-6R, IL-9, IL-9R, IL-31, IL-31R, IL-17E (IL-25), and IL-17ER (IL-25R). In some cases, unregulated KLK activity in the epidermis results in and / or is associated with Th2 cell activation, leading to secretion of Th2 cytokines. Elevated Th2 cytokines may further contribute to KLK overactivation (FIG. 2). Therapeutic antibodies have been developed to suppress Th2 cytokine mediated inflammation by targeting Th2 cytokines and / or their respective receptors (referred to as Th2-targeting antibodies), for example, anti- IL-13 antibody, or anti-IL-13R antibody.[000141] In some embodiments, antibodies provided herein comprise at least one antigen- specific binding site that specifically binds to IL- 13 or a receptor thereof.Antibodies targeting Th2 cytokines or receptors thereof include, but are not limited to, anti- IL-13 antibodies and anti-IL-13R antibodies. Any suitable IL- 13 targeting antibodies can be used in the methods and compositions, including but not limited to those described in Table 2.Table 2: Examples of IL-13 targeting Antibodies[000142] In some embodiments, an IL- 13 targeting antibody comprises an antigenspecific binding site for IL- 13 or a receptor thereof. In some embodiments, an IL- 13 targeting antibody comprises an antigen- specific binding site for IL- 13 or IL-13R derived from any known anti-IL-13 or a receptor thereof, e.g., anti-IL-13 / anti-IL-13R antibodies described in W02005062972, which is published on 07 / 14 / 2005, and which is entitled “Treatment of cancer with novel anti-il 13 monoclonal antibodies”; WO 2005062967, which is published on 07 / 14 / 2005, and which is entitled “Novel anti-il 13 antibodies and uses thereof’;, WO 2008140455, which is published on 05 / 15 / 2007, and which is entitled “Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies”; or WO2023245187 , which is published on 12 / 21 / 2023, and which is entitled “Antibodies that bind interleukin 13 and methods of use”; US6703488, which published on 03 / 09 / 2004, and which is entitled, Antibody / Receptor Targeting Moiety For Enhanced Delivery Of Armed Ligand; US2005058645, which published on 03 / 17 / 2005, and which is entitled, Monoclonal Antibody Against Interleukin- 13 Receptor Alpha 1 (IL-13Ralphal); US2005154192, which published on 07 / 14 / 2005, and which is entitled, Anti-IL13 Receptor Alphal Neutralizing Antibody; US2006099652, which published on 05 / 11 / 2006, and which is entitled, IL 13 Receptor Alpha 2 Antibody And Methods Of Use; US2006140948, which published on 06 / 29 / 2006, and which is entitled, Fully Human Monoclonal Antibodies To IL- 13; US2006263356, which published on 11 / 23 / 2006, and which is entitled, Antibodies AgainstIL-13 Receptor Alphal And Uses Thereof; US2007048785, which published on 03 / 01 / 2007, and which is entitled, Anti-IL-13 Antibodies And Complexes; US2007128192, which published on 06 / 07 / 2007, and which is entitled, Human Antibody Molecules For IL- 13; W007080174, which published on 07 / 19 / 2007, and which is entitled, Immunoglobulins; US2007258979, which published on 11 / 08 / 2007, and which is entitled, Chimeric And Humanised Monoclonal Antibodies Against Interleukin- 13; US2008008648, which published on 01 / 10 / 2008, and which is entitled, Treatment Of Cancer With A Novel Anti- IL13 Monoclonal Antibody; US2008044420, which published on 02 / 21 / 2008, and which is entitled, Anti-IL-13 Antibodies, Compositions, Methods And Uses; US2008166343, which published on 07 / 10 / 2008, and which is entitled, High Affinity Antibody Antagonists Of Interleukin- 13 Receptor Alpha 1; US2008171014, which published on 07 / 17 / 2008, and which is entitled, Interleukin- 13 Binding Proteins; US2008248048, which published on 10 / 09 / 2008, and which is entitled, Interleukin- 13 Antibody Composition; US2008267959, which published on 10 / 30 / 2008, and which is entitled, Anti-IL13 Human Antibodies;US2009060906, which published on 03 / 05 / 2009, and which is entitled, Anti-IL-13 Antibody Formulations And Uses Thereof; US2009148905, which published on 06 / 11 / 2009, and which is entitled, Antigen-Binding Constructs; US2009285799, which published on 11 / 19 / 2009, and which is entitled, Antibody Antagonists Of Interleukin- 13 Receptor Alphal; WO09138413, which published on 11 / 19 / 2009, and which is entitled, Single Domain Antibodies That Bind IL-13; US2010226923, which published on 09 / 09 / 2010, and which is entitled, Antibodies That Bind IL-4 And / Or IL- 13 And Their Uses; US2010260773, which published on 10 / 14 / 2010, and which is entitled, Antibody Molecules Having Binding Specificity For Human IL-13; US2011052597, which published on 03 / 03 / 2011, and which is entitled, Anti- IL-13R Alphal Antibodies And Their Uses Thereof; US2011206687, which published on 08 / 25 / 2011, and which is entitled, Isolation And Purification Of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography; US2012045438, which published on 02 / 23 / 2012, and which is entitled, Engineered Anti-IL-13 Antibodies, Compositions, Methods And Uses; US2012093830, which published on 04 / 19 / 2012, and which is entitled, Single Domain Antibodies That Bind IL-13; WO13103783, which published on 07 / 11 / 2013, and which is entitled, Murine IL-13 Antibodies; US2014341913, which published on 11 / 20 / 2014, and which is entitled, Methods And Compositions For Treating Asthma Using Anti-IL-13 Antibodies; US2014348855, which published on 11 / 27 / 2014, and which is entitled, Antibody Formulations; US2015225479, which published on 08 / 13 / 2015, and which is entitled, Anti- IL-4 / Anti-IL- 13 Bispecific Antibody / Polyglutamate Formulations; US2015266962, whichpublished on 09 / 24 / 2015, and which is entitled, Anti-IL-13 Receptor Alpha 2 Antibodies And Antibody-Drug Conjugates; US2016075777, which published on 03 / 17 / 2016, and which is entitled, Anti-IL-4 / Anti-IL-13 Bispecific Antibody Formulations; US2016319012, which published on 11 / 03 / 2016, and which is entitled, Methods And Compositions Comprising Purified Recombinant Polypeptides; US2017145089, which published on 05 / 25 / 2017, and which is entitled, Anti-IL4-Il 13 Bispecific Antibodies; WO17191627, which published on 11 / 09 / 2017, and which is entitled, Antibodies To Interleukin 13 Receptor Alpha-1 (IL-13R Alpha 1) And Uses Thereof; US2017334985, which published on 11 / 23 / 2017, and which is entitled, Anti-IL- 13 / 11- 17 Bispecific Antibodies And Uses Thereof; WO19096219, which published on 05 / 23 / 2019, and which is entitled, Humanized Anti-IL- 13 Antibody And Preparation Method And Use Thereof; US2019247303, which published on 08 / 15 / 2019, and which is entitled, Inhalable Powder Composition Comprising IL-13 Antibody;US2019309059, which published on 10 / 10 / 2019, and which is entitled, IL- 13 Antibody And Preparation Method And Use Thereof; US2020165347, which published on 05 / 28 / 2020, and which is entitled, Method Of Treatment Using IL-13R Antibody; US2021277131, which published on 09 / 09 / 2021, and which is entitled, Treatment Employing Anti-Il-L3R Antibody Or Binding Fragment Thereof; US2021380674, which published on 12 / 09 / 2021, and which is entitled, Methods Of Treatment Of Diseases In Which IL-13 Activity Is Detrimental Using Anti-IL- 13 Antibodies; US2022033508, which published on 02 / 03 / 2022, and which is entitled, Anti-IL 13R Alpha2 Antibodies; WO22174808, which published on 08 / 25 / 2022, and which is entitled, Antibody Against IL-13Ra2 And Use Thereof; US2022305104, which published on 09 / 29 / 2022, and which is entitled, Methods Of Treating Atopic Dermatitis;US2023002484, which published on 01 / 05 / 2023, and which is entitled, Treatment Of Atopic Dermatitis Employing Anti-IL-13Ral Antibody Or Binding Fragment Thereof;WO23287590, which published on 01 / 19 / 2023, and which is entitled, IL- 13 Antibodies For The Treatment Of Atopic Dermatitis; WO23019260, which published on 02 / 16 / 2023, and which is entitled, IL- 13 Antibodies For The Treatment Of Atopic Dermatitis; WO23023497, which published on 02 / 23 / 2023, and which is entitled, Anti-IL- 13 Antibody Formulation; US2023084464, which published on 03 / 16 / 2023, and which is entitled, Antibody With Binding Specificity For Human IL-13; US2023087378, which published on 03 / 23 / 2023, and which is entitled, Multi-Specific Antibody With Binding Specificity For Human IL- 13 And 11-17; W023075700, which published on 05 / 04 / 2023, and which is entitled, Anti-IL-13R Antibody Formulation; WO23075702, which published on 05 / 04 / 2023, and which is entitled, Anti-IL-13R Antibody Formulation; US2023183364, which published on 06 / 15 / 2023, andwhich is entitled, Anti-IL13R-Alpha2 Antibodies, Antigen-Binding Fragments And Uses Thereof; WO23163659, which published on 08 / 31 / 2023, and which is entitled, Glycosylated Form Of Anti-IL13R Antibody; US2023357381, which published on 11 / 09 / 2023, and which is entitled, Multispecific Antibodies Targeting IL-13 And 11-18; WO23215769, which published on 11 / 09 / 2023, and which is entitled, IL-13 Antibodies For The Treatment Of Atopic Dermatitis; WO23245187, which published on 12 / 21 / 2023, and which is entitled, Antibodies That Bind Interleukin 13 And Methods Of Use; WO24043837, which published on 02 / 29 / 2024, and which is entitled, High Concentration Anti-IL13R Antibody Formulation; US2024117030, which published on 04 / 11 / 2024, and which is entitled, Multispecific Antibodies And Uses Thereof; US2024158521, which published on 05 / 16 / 2024, and which is entitled, Dna-Encoded Bispecific Antibodies Targeting IL13Ra2 And Methods Of Use In Cancer Therapeutics; WO08140455, which published on 11 / 20 / 2008, and which is entitled, Treatment Of Radiation And Chemo-Therapy Induced Fibrosis Using Novel Anti-IL 13 Monoclonal Antibodies; and W024099310, which published on 05 / 16 / 2024, and which is entitled, Anti-IL- 13 Long- Acting Nanobody Sequence And Use Thereof, the contents describing an anti-IL-13 antibody in each of which are incorporated herein by reference. In some embodiments, an IL- 13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of a VH of any one of the anti-IL-13 antibodies or anti-IL-13R antibodies in Table 2, and a LC CDR1, LC CDR2, and LC CDR3 of a VL of any one of the anti-IL-13 antibodies or anti-IL-13R antibodies in Table 2. In some embodiments, an IL- 13 targeting antibody comprises a VH of any one of the anti-IL-13 antibodies or the anti-anti-IL-13R antibodies in Table 2, and a VL of any one of the anti-IL-13 antibodies or the anti-anti-IL-13R antibodies in Table 2. In some embodiments, an IL-13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of Anrukinzumab, and a LC CDR1, LC CDR2, and LC CDR3 of Anrukinzumab. In some embodiments, an IL-13 targeting antibody comprises a VH of Anrukinzumab, and a VL of Anrukinzumab. In some embodiments, an IL- 13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of lebrikizumab, and a LC CDR1, LC CDR2, and LC CDR3 of Lebrikizumab. In some embodiments, an IL- 13 targeting antibody comprises a VH of Lebrikizumab, and a VL of Lebrikizumab. In some embodiments, an IL- 13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of Tralokinumab, and a LC CDR1, LC CDR2, and LC CDR3 of Tralokinumab. In some embodiments, an IL- 13 targeting antibody comprises a VH of Tralokinumab, and a VL of Tralokinumab. In some embodiments, an IL-13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of Eblasakimab, and a LC CDR1, LC CDR2, and LC CDR3 ofEblasakimab. In some embodiments, an IL- 13 targeting antibody comprises a VH of Eblasakimab, and a VL of Eblasakimab. In some embodiments, an IL-13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of Cendakimab, and a LC CDR1, LC CDR2, and LC CDR3 of Cendakimab. In some embodiments, an IL-13 targeting antibody comprises a VH of Cendakimab, and a VL of Cendakimab. In some embodiments, an IL- 13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of Dectrekumab, and a LC CDR1, LC CDR2, and LC CDR3 of Dectrekumab. In some embodiments, an IL- 13 targeting antibody comprises a VH of Dectrekumab, and a VL of Dectrekumab. In some embodiments, an IL-13 targeting antibody comprises a HC CDR1, HC CDR2, HC CDR3 of APG777, and a LC CDR1, LC CDR2, and LC CDR3 of APG777. In some embodiments, an IL-13 targeting antibody comprises a VH of APG777, and a VL of APG777.(c) Multispecific Antibodies[000143] In some embodiments, an antibody provided here is a multi- specific antibody (e.g., a bispecific antibody). Lor example, in some embodiments, one or more anti- KLK5 / KLK7 antibodies may be combined with one or more different anti-KLK5 / KLK7 antibody to produce a multi- specific or a bispecific anti-KLK5 / KLK7 antibody. Lor example, one or more anti-KLK5 / KLK7 antibody as described herein (Table la and Table lb), can be combined with one or more different anti-KLK5 / KLK7 antibody described herein (Table la and Table lb) to produce a multi- specific antibody.[000144] In some embodiments, one or more anti-KLK5 / KLK7 antibodies may be combined with any other appropriate therapeutic antibodies to produce a multi- specific or a bispecific anti-KLK5 / KLK7 / additional target antibody. Lor example, an anti-KLK5 / KLK7 antibody as described herein (Table la and Table lb), can be combined with any appropriate antibody (e.g., IL-13 targeting antibodies as described in Table 2) to produce a bispecific antibody.[000145] In some aspects, the present disclosure provides a bispecific antibody comprising at least one antigen- specific binding site that specifically binds KLK5 and KLK7 and at least one antigen- specific binding site that specifically binds to IL- 13 or receptor thereof.[000146] Table 6 below sets forth possible arm configurations for an anti-KLK5 / KLK7 + IL- 13 targeting bispecific antibody. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 targeting bispecific antibody comprises one arm comprising CDRs and / or a VH and / or VL, the sequences of which are derived from or correspond to or are the same as the sequences ofthe CDRs and / or VH and / or VL of an antibody listed in the left column of Table 6, and a second arm comprising CDRs and / or VH / VL, the sequences of which are derived from or correspond to or are the same as the sequences of CDRs and / or VH and / or VL of an anti-IL- 13 antibody listed in the corresponding row in the right column of Table 6 or of another suitable antibody disclosed herein. The CDRs and VH / VL of the respective antibodies are listed in Tables la and 2.Table 6: Anti-KLK5 / KLK7 + Th2 Bispecific Antibody Arm Configurations[000147] In some embodiments, an anti-KLK5 / KLK7 + Th2 targeting bispecific antibody comprises one arm comprising CDRs and / or VH / VL pair, the sequences of which are derived from or correspond to or are the same as the sequences of the CDRs and / or VH / VL of an anti-KLK5 / KLK7 antibody listed in Table la, and a second arm comprising CDRs and / or VH / VL, the sequences of which are derived from or correspond to or are the same as the sequences of CDRs and / or VH / VL of an anti-IL-13 or anti-IL-13R antibody listed in Table 2, Table 6, or elsewhere herein. In some embodiments, an anti-KLK5 / KLK7 + Th2 bispecific antibody may include one arm comprising an antigen- specific binding site targeting KLK5 and KLK7, and a second arm comprising an antigen specific binding site that does not target IL- 13 or IL-13R.[000148] In some embodiments, a bispecific antibody described herein comprises at least one antigen- specific binding site that specifically binds KLK5 and KLK7 (e.g., KLK5 / KLK7-Dual-Ab4) and at least one antigen- specific binding site that specifically binds to IL- 13 or IL-13R (anti-KLK5 / KLK7 + IL- 13 bispecific antibody). Such antigen- specific binding sites may be derived from or correspond to or the same as any one of the anti- KLK5 / KLK7 antibodies and IL-13 / IL-13R targeting antibodies disclosed herein.[000149] Interleukin (IL)- 13 is a cytokine involved in the pathogenesis of skin barrier disease (e.g., atopic dermatitis (AD)). In some embodiments, IL-13 is a driver of type-2 T- helper inflammation. In some embodiments, IL- 13 is overexpressed in lesional skin in subjects with skin barrier disease. In some embodiments, upon release in peripheral skin, IL- 13 activates its receptors, recruits inflammatory cells, and / or modifies the skin microbiome. In some embodiments, IL-13 also reduces the expression of epidermal barrier proteins and activates sensory nerve mediating the itch transmission signal. In some embodiments, blocking IL- 13 signaling in combination with inhibition of KLK5 / KLK7 is effective in treating any of the diseases described herein.[000150] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein comprises at least one antigen- specific binding site that specifically binds to the active sites of KLK5 and KLK7. In some embodiments, an anti-KLK5 / KLK7 + IL- 13bispecific antibody described herein comprises the at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 that is a binding site of a dual inhibitor antibody that specifically binds to KLK5 and KLK7 (e.g., any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7-Dual-Ab3, KLK5 / KLK7-Dual-Abl). In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises one arm comprising at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 that comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the antibodies listed in Table la and Table lb (e.g., any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7-Dual-Ab3, KLK5 / KLK7- Dual-Ab4), and one arm comprising at least one antigen- specific binding site that specifically binds to IL-13 or IL-13R that comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the anti-IL-13 or anti-IL-13R antibodies listed in Table 2. In some embodiments, an anti-KLK5 / KLK7-IL-13 bispecific antibody comprises one arm comprising at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a VH at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a VH of any one of the antibodies listed in Table la and Table lb, and / or a VL at least 80% e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a VL of any one of the antibodies listed in Table la and Table lb, and one arm comprising at least one antigen- specific binding site that specifically binds to IL-13 or IL-13R comprises a VH at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a VH of any one of the anti-IL-13 or anti-IL-13R antibodies listed in Table 2, and / or a VL at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a VL of any one of the anti-IL-13 or anti-IL-13R antibodies listed in Table 2.[000151] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 7, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 8. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least oneantigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 13, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 17, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 21, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.[000152] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 1, a HC CDR2 having the amino acid sequence of SEQ ID NO: 2, a HC CDR3 having the amino acid sequence of SEQ ID NO: 3, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 6. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 10, a HC CDR3 having the amino acid sequence of SEQ ID NO: 11, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12. In some embodiments, an anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 15, a HC CDR3 having the amino acid sequence of SEQ ID NO: 16, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least oneantigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1 having the amino acid sequence of SEQ ID NO: 18, a HC CDR2 having the amino acid sequence of SEQ ID NO: 19, a HC CDR3 having the amino acid sequence of SEQ ID NO: 20, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.[000153] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, an anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 13, and a VL comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 17, and a LC CDR1, LC CDR2 and a VL comprising the amino acid sequence of SEQ ID NO: 14. In some embodiments, an anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a VH comprising the amino acid sequence of SEQ ID NO: 21, and a VL comprising the amino acid sequence of SEQ ID NO: 14.[000154] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises an antigenspecific binding site for IL- 13 derived from any known anti-IL-13 or a receptor thereof, e.g., anti-IL-13 / anti-IL-13R antibodies described in W02005062972, WO 2005062967, WO 2008140455, or WO2023245187, the contents describing an anti-IL-13 antibody in each of which are incorporated herein by reference. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the anti-IL-13 antibodies or anti-IL-13R antibodies listed in Table 2. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13or IL-13R comprises a VH and / or a VL of any one of the anti-IL-13 antibodies or anti-IL- 13R antibodies in Table 2.[000155] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Anrukinzumab. In some embodiments, the anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 53, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 54. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 62, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 63, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a LC CDR2 comprising the amino acid sequence of RAS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 68, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 69, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acidsequence of SEQ ID NO: 53, and a VL comprising the amino acid sequence of SEQ ID NO: 54.[000156] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Lebrikizumab. In some embodiments, the anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 33. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LC CDR2 comprising the amino acid sequence of LAS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 45. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acidsequence of SEQ ID NO: 32 and a VL comprising the amino acid sequence of SEQ ID NO: 33.[000157] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Lebrikizumab. In some embodiments, the KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, and at least one antigen- specific binding site that specifically binds IL- 13 comprising a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 33. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1comprising the amino acid sequence of SEQ ID NO: 40, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 45. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 50. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a VH comprising the amino acid sequence of SEQ ID NO: 21 and a VL comprising the amino acid sequence of SEQ ID NO: 14, and at least one antigenspecific binding site that specifically binds IL- 13 comprising a VH comprising the amino acid sequence of SEQ ID NO: 32 and a VL comprising the amino acid sequence of SEQ ID NO: 33.[000158] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from APG777 (i.e., construct 133 as described in WO2023245187). In some embodiments, the anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 657, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 658.1n some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprisesat least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 655, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LC CDR2 comprising the amino acid sequence of LAS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 45. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 656, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acid sequence of SEQ ID NO: 657 and a VL comprising the amino acid sequence of SEQ ID NO: 658.[000159] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from APG777. In some embodiments, the KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, and at least one antigen- specific binding site that specifically binds IL- 13 comprising a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 657, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQID NO: 658. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigenspecific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 655, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 45. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 19, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 20, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 656, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a HC CDR3 comprising the amino acid sequence of SEQID NO: 48, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 / KLK7 comprising a VH comprising the amino acid sequence of SEQ ID NO: 21 and a VL comprising the amino acid sequence of SEQ ID NO: 14, and at least one antigenspecific binding site that specifically binds IL- 13 comprising a VH comprising the amino acid sequence of SEQ ID NO: 657 and a VL comprising the amino acid sequence of SEQ ID NO: 658.[000160] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Tralokinumab. In some embodiments, the anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 77, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 78, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 81. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 83, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 84, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a LC CDR2 comprising the amino acid sequence of DDG, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 87. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a HC CDR2comprising the amino acid sequence of SEQ ID NO: 89, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 90, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acid sequence of SEQ ID NO: 74, and a VL comprising the amino acid sequence of SEQ ID NO: 75.[000161] [000155] In some embodiments, an anti-KLK5 / KLK7 + IL-13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7-Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL-13R derived from Eblasakimab. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL-13R comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 94, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL-13R comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 96, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 97, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 98, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 99, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 100, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 101. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL-13R comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 102, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 103, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 104, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 105, a LC CDR2 comprising the amino acid sequence of GAS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 107. In some embodiments, the anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL-13R comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 108, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 109, a HC CDR3comprising the amino acid sequence of SEQ ID NO: 110, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 111, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 112, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 113. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL-13R comprises a VH comprising the amino acid sequence of SEQ ID NO: 94, and a VL comprising the amino acid sequence of SEQ ID NO: 95.[000162] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Cendakimab. In some embodiments, the anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 114, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 115. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 116, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 117, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 118, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 119, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 120, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 121. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 122, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 123, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 124, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 125, a LC CDR2 comprising the amino acid sequence of YTS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 127. In some embodiments, the anti-KLK5 / KLK7 + IL-13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 128, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 129, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 130, a LC CDR1 comprising the aminoacid sequence of SEQ ID NO: 131, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 132, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 133. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acid sequence of SEQ ID NO: 114, and a VL comprising the amino acid sequence of SEQ ID NO: 115.[000163] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprises at least one antigen- specific binding site that specifically binds to KLK5 / KLK7 derived from any one of KLK5 / KLK7-Dual-Abl, KLK5 / KLK7-Dual-Ab2, KLK5 / KLK7- Dual-Ab3, KLK5 / KLK7-Dual-Ab4, and at least one antigen- specific binding site that specifically binds IL- 13 derived from Dectrekumab. In some embodiments, the anti- KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 134, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 135. In some embodiments, a Th2 targeting antibody comprises an antigen-specific binding site for IL- 13 or a receptor thereof. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 136, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 137, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 138, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 139, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 140, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 141. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 142, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 143, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 144, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 145, a LC CDR2 comprising the amino acid sequence of DAS, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 147. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 148, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 149, a HC CDR3 comprising the amino acid sequence of SEQ IDNO: 150, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 151, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 152, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 153. In some embodiments, the anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site that specifically binds IL- 13 comprises a VH comprising the amino acid sequence of SEQ ID NO: 134, and a VL comprising the amino acid sequence of SEQ ID NO: 135.[000164] Due to the change in size, valency, structure, arrangement, valencies, flexibility and geometry, heavy chain / light chain paring, etc., it is known that a bispecific antibody may not retain the same binding property to each antigen as compared to the parental antibodies from which the bispecific antibody derives from (see, e.g., Brinkmanna et al., The making of bispecific antibodies, MAbs. 2017 Feb-Mar; 9(2): 182-212).[000165] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprising the CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of KLK5 / KLK7-Dual-Ab4 and CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of an anti-IL-13 antibody such as lebrikizumab) retains a similar range of binding affinity (e.g., no more than 10% difference, no more than 20% difference, no more than 30% difference, no more than 40% difference, no more than 50% difference, no more than 10% difference, less than 10 fold difference, less than 9 fold difference, less than 8 fold difference, less than 7 fold difference, less than 6 fold difference, less than 5 fold difference, less than 4 fold difference, less than 3 fold difference, less than 2 fold difference, or less than 1 fold difference) relative to binding affinity KLK5 / KLK7-Dual-Ab4 to KLK5 / KLK7 and lebrikizumab to IL- 13. As such, in some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprising the CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of KLK5 / KLK7-Dual-Ab4 and CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of an anti-IL-13 antibody such as lebrikizumab retains a similar range of binding affinity (e.g., no more than 10% difference, no more than 20% difference, no more than 30% difference, no more than 40% difference, no more than 50% difference, no more than 10% difference, less than 10 fold difference, less than 9 fold difference, less than 8 fold difference, less than 7 fold difference, less than 6 fold difference, less than 5 fold difference, less than 4 fold difference, less than 3 fold difference, less than 2 fold difference, or less than 1 fold difference) relative to the binding affinity of KLK5 / KLK7- Dual-Ab4. As such, in some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprising the CDRs and / or VH / VL derived from or corresponds to or the same as the CDRsand / or VH / VL of KLK5 / KLK7-Dual-Ab4 and CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of an anti-IL-13 antibody such as lebrikizumab retains a similar range of binding affinity (e.g., no more than 10% difference, no more than 20% difference, no more than 30% difference, no more than 40% difference, no more than 50% difference, no more than 10% difference, less than 10 fold difference, less than 9 fold difference, less than 8 fold difference, less than 7 fold difference, less than 6 fold difference, less than 5 fold difference, less than 4 fold difference, less than 3 fold difference, less than 2 fold difference, or less than 1 fold difference) relative to the binding affinity of the anti-IL-13 antibody such as lebrikizumab) that the bispecific antibody derives from or corresponds to or the same as. Binding affinity of the bispecific antibody and the parental antibodies of the bispecific antibody can be measured by any suitable method, e.g., BIAcore, ELISA, etc.[000166] In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody retains a similar range of inhibitory activity (e.g., no more than 10% difference, no more than 20% difference, no more than 30% difference, no more than 40% difference, no more than 50% difference, no more than 10% difference, less than 10 fold difference, less than 9 fold difference, less than 8 fold difference, less than 7 fold difference, less than 6 fold difference, less than 5 fold difference, less than 4 fold difference, less than 3 fold difference, less than 2 fold difference, or less than 1 fold difference) to each antigen (e.g., KLK5 / KLK7, and a Th2 target described herein) relative to the inhibitory activity of the antibody each of the antigenspecific binding sites of the bispecific antibody derives from or corresponds to or the same as. In some embodiments, an anti-KLK5 / KLK7 + IL- 13 bispecific antibody comprising the CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of KLK5 / KLK7-Dual-Ab4 and CDRs and / or VH / VL derived from or corresponds to or the same as the CDRs and / or VH / VL of an anti-IL-13 antibody such as lebrikizumab) retains a similar range of inhibitory activity (e.g., no more than 10% difference, no more than 20% difference, no more than 30% difference, no more than 40% difference, no more than 50% difference, no more than 10% difference, less than 10 fold difference, less than 9 fold difference, less than 8 fold difference, less than 7 fold difference, less than 6 fold difference, less than 5 fold difference, less than 4 fold difference, less than 3 fold difference, less than 2 fold difference, or less than 1 fold difference) relative to the inhibitory activity of KLK5 / KLK7-Dual-Ab4 to KLK5 / KLK7 protease activity and lebrikizumab to IL- 13 signaling. Inhibitory activity of the bispecific antibody and the parental antibodies can bemeasured by any suitable methods, e.g., KLK5 / KLK7 protease activity to BOC-Val-Pro-Arg- AMC and / or KHLF-AMC, RT-PCR, western blot, etc.[000167] In some embodiments, one or more anti-KLK5 / KLK7 antibodies may be combined with any other appropriate anti-KLK7 antibody to produce a multi- specific or a bispecific anti-KLK5 / KLK7 antibody. For example, an anti-KLK5 / KLK7 antibody as described herein (Table la and Table lb), can be combined with other any appropriate anti- KLK7 antibody to produce a bispecific antibody. Non-limiting examples of appropriate anti- KLK7 antibodies are provided in US Patent Application Publication No.: 2021-0130492 entitled, “ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5 / KLK7 ANTIBODIES, AND METHODS OF USE”, published on May 6, 2021; International Patent Application Publication No.: WO2021226695 entitled, RECOMBINANT HUMAN ANTIBODIES FOR INHIBITING HUMAN TISSUE KALLIKREIN 7 (KLK7) AND USE IN DISEASES RELATED TO THE PROCESS OF SKIN DESQUAMATION”, published November 18, 2021; and International Patent Application Publication No.: W02005075667 entitled, “DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH KALLIKREIN 7 (KLK7)”, published on August 18, 2005, the contents of which are incorporated herein by reference. [000168] In some embodiments, one or more anti-KLK5 / KLK7 antibodies may be combined with any appropriate anti-KLK5 antibody to produce a multi- specific or a bispecific anti-KLK5 / KLK7 antibody. For example, a KLK5 / KLK7 antibody as described herein (Table la and Table lb), can be combined with any appropriate anti-KLK5 antibody. Non-limiting examples of anti-KLK5 antibodies are provided in US Patent No.: 11,292,828 entitled, “KLK5 INHIBITORY PEPTIDE”, granted on April 5, 2022; US Patent Application Publication No.: 2022-0306725 entitled, “KLK5 INHIBITORY PEPTIDE”, published on September 29, 2022; US Patent Application Publication No.: 2019-0078160 entitled, “USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE”, published on March 14, 2019; International Patent Application Publication No.: WO2021156171 entitled, “ANTIBODIES AGAINST KLK5”, published on August 12, 2021; International Patent Application Publication No.: WO2021156170 entitled, “ANTIBODIES AGAINST KLK5”, published on August 12, 2021; US Patent Application Publication No.: 2021-0301032 entitled, “ANTI-KLK5 ANTIBODIES AND METHODS OF USE”, published on September 30, 2021; and US Patent Application Publication No.: 2021-0130492 entitled, “ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5 / KLK7ANTIBODIES, AND METHODS OF USE”, published on May 6, 2021, the contents of which are incorporated herein by reference.[000169] In some embodiments, a multi- specific antibody comprises three, four, five, six, seven, eight, or more distinct antigen- specific binding sites. In some embodiments, each distinct antigen- specific binding site of a multi- specific antibody targets a different antigen. In some embodiments, each distinct antigen- specific binding site of a multi- specific antibody targets a different region of the same antigen. In some embodiments, a multi- specific antibody comprises distinct antigen- specific binding sites targeting different antigens and / or distinct antigen- specific binding sites targeting different regions of the same antigen. In some embodiments, a multi- specific antibody comprises at least one antigen- specific binding site targeting a first antigen and at least one antigen-specific binding site targeting a second antigen. In some embodiments, a multi- specific antibody comprises two or more antigenspecific binding sites targeting different regions of a first antigen and / or two or more antigenspecific binding sites targeting different regions of a second antigen.[000170] In some embodiments, a multi- specific antibody targets two antigens and contains one antigen- specific binding site for each antigen (1 + 1). In some embodiments, a multi- specific antibody targets two antigens and contains two antigen- specific binding sites for each antigen (2 + 2). In some embodiments, a multi- specific antibody targets two antigens and contains one antigen- specific binding site for one antigen and two antigenspecific binding sites for another antigen (1 + 2). In some embodiments, a multi- specific antibody targets two antigens and contains two antigen- specific binding sites for one antigen and three antigen- specific binding sites for another antigen (2 + 3). In some embodiments, a multi- specific antibody targets two antigens and contains three antigen- specific binding sites for one antigen and three antigen- specific binding sites for another antigen (3 + 3).[000171] In some embodiments, a multispecific antibody lacks Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibodydependent cellular phagocytosis (ADCP), complement fixation, and FcRn-mediated recycling. However, in some embodiments, a multi- specific antibody comprises one or more Fc regions that support Fc-mediated effector functions, such as antibody-dependent cell- mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement fixation, and FcRn-mediated recycling.[000172] In some embodiments, an antibody provided herein is a bispecific antibody. In some embodiments, a bispecific antibody comprises at least two different Fv regions. In some embodiments, a bispecific antibody comprises two different heavy chains, and twodifferent light chains. In some embodiments, a bispecific antibody comprises one or more IgG molecules. In some embodiments, a bispecific antibody comprises one or more IgG molecules that contain additional antigen- specific binding sites, e.g., IgG molecules that comprise an appended or modified Ig-like structure.[000173] In some embodiments, a bispecific antibody comprises two single-chain variable fragments (scFvs) connected via a linker. In some embodiments, a bispecific antibody comprises two single-domain antibodies, such as VH or VL domains, VHH, VNAR or Nanobodies connected via a linker e.g., a flexible glycine rich linker, such as a (G4S)3~i linkers). In some embodiments, a bispecific antibody is in a diabody format, such as described in P Holliger, T Prospero, and G Winter, "Diabodies": small bivalent and bispecific antibody fragments, Proc Natl Acad Sci U S A. 1993 Jul 15; 90(14): 6444-6448, the entire contents of which are incorporated herein by reference in their entirety. In some embodiments, a bispecific antibody is a Fab fusion protein, such as a Fab-Fab fusion protein, a Fab-scFv fusion protein, or a Fab-Fv fusion protein. In some embodiments, a bispecific antibody comprises an antigen-binding site, e.g., a scFv, that is modified to contain a second and distinct antigen- specific binding site as an integral part of the antibody, e.g., scFv.[000174] In some embodiments, a bispecific antibody is in a fragment-based format, symmetric format, or asymmetric format. In some embodiments, a bispecific antibody in a fragment-based format does not comprise an Fc region. In some embodiments, a bispecific antibody is in a tandem VHHs, a tandem scFvs, a DART, a diabody, a F(ab)2, a scFv-Fab, a tandem VHHs, a (scFv)2-Fab, or a tandem diabodies format. In some embodiments, a bispecific antibody is in an asymmetric format selected from: arat-mouse hybrid IgG, hetero H HL exchange and / or assembly IgG, hetero H forced HL IgG, cH IgG, hetero H CrossMab, scFv-Fab IgG, DART-Fc, LP-DART, CODV-Fab-TL, HLE-BiTE, and F(ab)3CrossMab format. In some embodiments, a bispecific antibody is in a symmetrical format selected from: IgG-(scFv)2, Bs4Ab, DVD-Ig, tetravalent DART-Fc, (scFV)4-Fc, CODV-Ig, two-in- one, mAb2, F(ab)4 CrossMab, and tandem VHH-Fc format.[000175] In some embodiments, a bispecific antibody is engineered to facilitate formation via the knobs-into-holes technique, e.g., to facilitate heterodimerization. The knobs-into-holes technique may be used, in some embodiments, to produce bispecific IgG molecules, trivalent Ig-like antibodies, bispecific Fc and CH3 fusion proteins, and other formats, as discussed in Ridgway JB, et al., 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; Atwell S, et al., Stable heterodimers from remodeling the domain interface of a homodimer using a phagedisplay library, J Mol Biol 1997; 270:26-35; and Merchant AM, et al., An efficient route to human bispecific IgG, Nat Biotechnol 1998; 16:677-681, the entire contents of each of which are incorporated herein by reference in their entireties.[000176] In some embodiments, a bispecific antibody lacks Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibodydependent cellular phagocytosis (ADCP), complement fixation, and / or FcRn-mediated recycling. However, in some embodiments, a bispecific antibody comprises one or more Fc regions that support Fc-mediated effector functions, such as antibody-dependent cell- mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement fixation, and FcRn-mediated recycling.III. Preparation of Antibodies[000177] Antibodies described herein can be made by any method known in the art. See, for example, Harlow and Lane, (1998) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York.[000178] In some embodiments, antibodies specific to a target antigen (e.g., KLK5 and / or KLK7) can be made by the conventional hybridoma technology. The full-length target antigen or a fragment thereof, optionally coupled to a carrier protein such as KLH, can be used to immunize a host animal for generating antibodies binding to that antigen. The route and schedule of immunization of the host animal are generally in keeping with established and conventional techniques for antibody stimulation and production, as further described herein. General techniques for production of mouse, humanized, and human antibodies are known in the art and are described herein. It is contemplated that any mammalian subject including humans or antibody producing cells therefrom can be manipulated to serve as the basis for production of mammalian, including human hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally, intramuscularly, orally, subcutaneously, intraplantar, and / or intradermally with an amount of immunogen, including as described herein.[000179] In some embodiments, bispecific antibodies targeting two different antigens (e.g., KLK5 / KLK7 and IL- 13 or receptor thereof) can be made by suitable methods, e.g., as described by Nature Reviews Drug Discovery volume 18, pages 585-608 (2019) and Brinkmann U and Kontermann EE, The making of bispecific antibodies, MAbs. 2017 Feb / Mar;9(2): 182-212. In some embodiments, an anti-KLK5 / KLK7 + IL-13 cytokine or receptor thereof can be produced by expressing the VH and / or VL of one arm, and the VHand / or VL of the other art in one or more host cells. In some embodiments, the coding sequence for the arm specifically binds to KLK5 / KLK7 are described herein. In some embodiments, the coding sequence for the arm specifically binds to IL- 13 or receptor thereof can be developed to express the amino acid sequences of the IL- 13 targeting antibodies described herein. In some embodiments, different chains of a bispecific antibody can be assembled to form the bispecific antibody using any suitable methods.[000180] If desired, an antibody (monoclonal or polyclonal) of interest (e.g., produced by a hybridoma) may be sequenced and the polynucleotide sequence may then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for future use. In an alternative, the polynucleotide sequence may be used for genetic manipulation to "humanize" the antibody or to improve the affinity (affinity maturation), or other characteristics of the antibody. For example, the constant region may be engineered to more resemble human constant regions to avoid immune response if the antibody is used in clinical trials and treatments in humans. It may be desirable to genetically manipulate the antibody sequence to obtain greater affinity to the target antigen and greater efficacy. It will be apparent to one of skill in the art that one or more polynucleotide changes can be made to the antibody and still maintain its binding specificity to the target antigen.[000181] In other embodiments, fully human antibodies can be obtained by using commercially available mice that have been engineered to express specific human immunoglobulin proteins. Transgenic animals that are designed to produce a more desirable (e.g., fully human antibodies) or more robust immune response may also be used for generation of humanized or human antibodies. Examples of such technology are XenomouseRTM from Amgen, Inc. (Fremont, CA) and HuMAb-MouseRTM and TC MouseTM from Medarex, Inc. (Princeton, NJ) or H2L2 mice from Harbour Antibodies BV (Holland). In another alternative, antibodies may be made recombinantly by phage display or yeast technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and Winter et al., (1994) Annu. Rev. Immunol. 12:433-455. Alternatively, the phage display technology (McCafferty et al., (1990) Nature 348:552-553) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.[000182] Antigen-binding fragments of an intact antibody (full-length antibody) can be prepared via routine methods. For example, F(ab')2 fragments can be produced by pepsin digestion of an antibody molecule, and Fab fragments that can be generated by reducing thedisulfide bridges of F(ab')2 fragments. Genetically engineered antibodies, such as humanized antibodies, chimeric antibodies, single-chain antibodies, and bi-specific antibodies, can be produced via, e.g., conventional recombinant technology. In one example, DNA encoding a monoclonal antibody specific to a target antigen can be readily isolated and sequenced using conventional procedures e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into one or more expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, human HEK293 cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. See, e.g., PCT Publication No. WO 87 / 04462. The DNA can then be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences, Morrison et al., (1984) Proc. Nat. Acad. Sci. 81:6851, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a nonimmunoglobulin polypeptide. In that manner, genetically engineered antibodies, such as “chimeric” or “hybrid” antibodies; can be prepared that have the binding specificity of a target antigen.[000183] A single-chain antibody can be prepared via recombinant technology by linking a nucleotide sequence coding for a heavy chain variable region and a nucleotide sequence coding for a light chain variable region. Preferably, a flexible linker is incorporated between the two variable regions.[000184] Antibodies obtained following a method known in the art and described herein can be characterized using methods well known in the art. For example, one method is to identify the epitope to which the antigen binds, or “epitope mapping.” There are many methods known in the art for mapping and characterizing the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in Chapter 11 of Harlow and Lane, Using Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999. In one example, epitope mapping can be accomplished using H / D-Ex (hydrogen deuterium exchange) coupled with proteolysis and mass spectrometry. In an additional example, epitope mapping can be used to determine the sequence to which an antibody binds. The epitope can be a linear epitope, i.e., contained in a single stretch of amino acids, or a conformational epitope formed by a three-dimensional interaction of amino acids that may not necessarily be contained in a single stretch (primary structure linear sequence). Peptides of varying lengths (e.g., at least 4-6 amino acids long) can be isolated or synthesized (e.g., recombinantly) and used for binding assays with an antibody. In another example, the epitope to which the antibody binds can be determined in a systematic screening by using overlapping peptides derived from the target antigen sequence and determining binding by the antibody. According to the gene fragment expression assays, the open reading frame encoding the target antigen is fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of the antigen with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then transcribed and translated into protein in vitro, in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled antigen fragments is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed on the surface of phage particles (phage libraries). Alternatively, a defined library of overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. In an additional example, mutagenesis of an antigen binding domain, domain swapping experiments and alanine scanning mutagenesis can be performed to identify residues required, sufficient, and / or necessary for epitope binding. Alternatively, competition assays can be performed using other antibodies known to bind to the same antigen to determine whether an antibody binds to the same epitope as the other antibodies. Competition assays are well known to those of skill in the art.[000185] In some examples, an antibody described herein is prepared by recombinant technology as exemplified below. Nucleic acids encoding the heavy and light chain of an antibody as described herein can be cloned into one expression vector, each nucleotide sequence being in operable linkage to a suitable promoter. In one example, each of the nucleotide sequences encoding the heavy chain and light chain is in operable linkage to a distinct promoter. Alternatively, the nucleotide sequences encoding the heavy chain and the light chain can be in operable linkage with a single promoter, such that both heavy and light chains are expressed from the same promoter. When necessary, an internal ribosomal entry site (IRES) can be inserted between the heavy chain and light chain encoding sequences. [000186] In some examples, the nucleotide sequences encoding the two chains of the antibody are cloned into two vectors, which can be introduced into the same or different cells. When the two chains are expressed in different cells, each of them can be isolated from thehost cells expressing such and the isolated heavy chains and light chains can be mixed and incubated under suitable conditions allowing for the formation of the antibody.[000187] Generally, a nucleic acid sequence encoding one or all chains of an antibody can be cloned into a suitable expression vector in operable linkage with a suitable promoter using methods known in the art. For example, the nucleotide sequence and vector can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the termini of a gene. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector. The selection of expression vectors / promoter would depend on the type of host cells for use in producing the antibodies.[000188] A variety of promoters can be used for expression of the antibodies described herein, including, but not limited to, cytomegalovirus (CMV) intermediate early promoter, a viral LTR such as the Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, the simian virus 40 (SV40) early promoter, E. coli lac UV promoter, and the herpes simplex tk virus promoter.[000189] Regulatable promoters can also be used. Such regulatable promoters include those using the lac repressor from E. coli as a transcription modulator to regulate transcription from lac operator bearing mammalian cell promoters [[Brown, M. et al., Cell, 49:603-612 (1987)]], those using the tetracycline repressor (tetR) [[Gossen, M., and Bujard, H., Proc. Natl. Acad. Sci. USA 89:5547-555115 (1992); Yao, F. et al., Human Gene Therapy, 9:1939-1950 (1998); Shockelt, P„ et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526 (1995)]]. Other systems include FK506 dimer, VP 16 or p65 using astradiol, RU486, diphenol murislerone, or rapamycin. Inducible systems are available from Invitrogen, Clontech and Ariad, among others.[000190] Regulatable promoters that include a repressor with the operon can be used. In one embodiment, the lac repressor from E. coli can function as a transcriptional modulator to regulate transcription from lac operator-bearing mammalian cell promoters [[M. Brown et al., Cell, 49:603-612 (1987)]]; Gossen and Bujard (1992); [[M. Gossen et al., Natl. Acad. Sci. USA, 89:5547-5551(1992)]] combined the tetracycline repressor (tetR) with the transcription activator (VP 16) to create a tetR-mammalian cell transcription activator fusion protein, tTa (tetR- VP 16), with the tetO bearing minimal promoter derived from the human cytomegalovirus (hCMV) promoter to create a tetR-tet operator system to control gene expression in mammalian cells. In one embodiment, a tetracycline inducible switch is used.The tetracycline repressor (tetR) alone, rather than the tetR-mammalian cell transcription factor fusion derivatives can function as potent trans-modulator to regulate gene expression in mammalian cells when the tetracycline operator is properly positioned downstream for the TATA element of the CMVIE promoter (Yao et al., Human Gene Therapy). One particular advantage of this tetracycline inducible switch is that it does not require the use of a tetracycline repressor-mammalian cells transactivator or repressor fusion protein, which in some instances can be toxic to cells (Gossen 5 et al., Natl. Acad. Sci. USA, 89:5547-5551 (1992); Shockett et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526 (1995)), to achieve its regulatable effects.[000191] Additionally, the vector can contain, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer / promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColEl for proper episomal replication; internal ribosome binding sites (IRESes), versatile multiple cloning sites; and T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art. Examples of polyadenylation signals useful to practice the methods described herein include, but are not limited to, human collagen I poly adenylation signal, human collagen II poly adenylation signal, and SV40 poly adenylation signal.[000192] One or more vectors (e.g., expression vectors) comprising nucleic acids encoding any of the antibodies (e.g., the nucleic acid coding sequence listed in Table 3) may be introduced into suitable host cells for producing the antibodies. Non-limiting examples of the host cells include Chinese hamster ovary (CHO) cells, dhfr- CHO cell, human embryonic kidney (HEK)-293 cells, verda reno (VERO) cells, nonsecreting null (NS0) cells, human embryonic retinal (PER.C6) cells, Sp2 / 0 cells, baby hamster kidney (BHK) cells, Madin- Darby Canine Kidney (MDCK) cells, Madin-Darby Bovine Kidney (MDBK) cells, and monkey kidney CV1 line transformed by SV40 (COS) cells. In some embodiments, the host cell expressing the antibodies described herein are CHO cells. The host cells can be cultured under suitable conditions for expression of the antibody or any polypeptide chain thereof. Such antibodies or polypeptide chains thereof can be recovered by the cultured cells (e.g., from the cells or the culture supernatant) via a conventional method, e.g., affinity purification. If necessary, polypeptide chains of the antibody can be incubated under suitableconditions for a suitable period of time allowing for production of the antibody. In some embodiments, the host cell comprises the nucleic acid encoding the heavy chain of the antibody described herein. In some embodiments, the host cell comprises the nucleic acid encoding the light chain of the antibody described herein. In some embodiments, the host cell comprises the nucleic acid encoding the heavy chain and the nucleic acid encoding the light chain.[000193] In some embodiments, methods for preparing an antibody described herein involve a recombinant expression vector that encodes both the heavy chain and the light chain of an antibody described herein, as also described herein. The recombinant expression vector can be introduced into a suitable host cell (e.g., a dhfr- CHO cell) by a conventional method, e.g., calcium phosphate mediated transfection. Positive transformant host cells can be selected and cultured under suitable conditions allowing for the expression of the two polypeptide chains that form the antibody, which can be recovered from the cells or from the culture medium. When necessary, the two chains recovered from the host cells can be incubated under suitable conditions allowing for the formation of the antibody.[000194] In one example, two recombinant expression vectors are provided, one encoding the heavy chain of the antibody and the other encoding the light chain of the antibody. Both of the two recombinant expression vectors can be introduced into a suitable host cell e.g., dhfr- CHO cell) by a conventional method, e.g., calcium phosphate-mediated transfection.[000195] Alternatively, each of the expression vectors can be introduced into a suitable host cell. Positive transformants can be selected and cultured under suitable conditions allowing for the expression of the polypeptide chains of the antibody. When the two expression vectors are introduced into the same host cells, the antibody produced therein can be recovered from the host cells or from the culture medium. If necessary, the polypeptide chains can be recovered from the host cells or from the culture medium and then incubated under suitable conditions allowing for formation of the antibody. When the two expression vectors are introduced into different host cells, each of them can be recovered from the corresponding host cells or from the corresponding culture media. The two polypeptide chains can then be incubated under suitable conditions for formation of the antibody.[000196] Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recovery of the antibodies from the culture medium. For example, some antibodies can be isolated by affinity chromatography with a Protein A or Protein G coupled matrix.[000197] Any of the nucleic acids encoding the heavy chain, the light chain, or both of an antibody as described herein (e.g., as provided in Table 3), vectors (e.g., expression vectors) containing such; and host cells comprising the vectors are within the scope of the present disclosure.Table 3: Nucleic acids Sequences encoding the VH / VL of anti-KLK5 / KLK7 antibodies listed in Table la

[0001] In some embodiments, the present disclosure provides an isolated nucleic acid comprising a sequence at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22,24, 26, or 27. In some embodiments, the present disclosure provides an isolated nucleic acid comprising a sequence at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 23,25, 659, or 660. In some embodiments, the present disclosure provides an isolated nucleic acid comprising a sequence at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22-27 or 659-660.

[0002] In some embodiments, the present disclosure provides an expression vector encoding the anti-KLK5 / KLK7 antibody described herein. In some embodiments, the expression vector comprises an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22, 24, 26, or 27. In some embodiment, the expression vector comprises an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs :23, 25, 659, or 660. In some embodiment, the expression vector comprises an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22-27 or 659-660.

[0003] In some embodiments, the anti-KLK5 / KLK7 antibodies described herein is produced by expressing in a recombinant cell: (i) an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22, 24, 26 or 27, and / or (ii) an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 23, 25, 659, or 660.

[0004] In some embodiments, the anti- KLK5 / KLK7 antibodies described herein is produced by expressing in a recombinant cell an expression vector comprising: (i) an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 22, 24, 26, and 27, and / or (ii) an isolated nucleic acid at least 60% (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 23, 25, 659, or 660.[000198] In some embodiments, the antibodies described herein are used to modulate the activity or function of at least one gene, protein, and / or nucleic acid. In some embodiments, the molecular payload is responsible for the modulation of a gene, protein, and / or nucleic acids. A molecular pay load may be a small molecule, protein, nucleic acid, oligonucleotide, or any molecular entity capable of modulating the activity or function of a gene, protein, and / or nucleic acid in a cell.[000199] In some embodiments, a multi- specific antibody comprises direct fusion or linking of different antigen- specific binding sites. In some embodiments, a multi- specific antibody comprises immunoglobulin-derived heteromerization domains to generate multispecific antibodies. In some embodiments, a multi- specific antibody can be formed by coexpression of different heavy chains and two different light chains. In some embodiments, a multi- specific antibody can be formed by co-expression of different heavy chains and a common light chain. In some embodiments, a multi- specific antibody comprises an engineered CHI domain (first constant Ig domain of the heavy chain) that facilitates proper heavy chain-light chain pairing, e.g., in such co-expression system, such as is disclosed in International Patent Application Publication Number W02021067404, “CHI DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME”, published on April 8, 2021, the contents of which are incorporated herein by reference.[000200] In some embodiments, a multi- specific antibody comprises variant CHI domain that pairs (e.g., preferentially pairs) with a particular variant CL domain. For example, in some embodiments, a multi- specific antibody comprises a heavy chain comprising a variant CHI domain that preferentially pairs with a variant CLK or CLZ. domain. Not limiting examples of such multi- specific antibody configurations are provided in International Patent Application Publication Number WO2022150787, “VARIANT CHI DOMAINS AND VARIANT CL DOMAINS ENGINEERED FOR PREFERENTIAL CHAIN PAIRING AND MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME”, published on July 14, 2022, the contents of which are incorporated herein by reference in their entirety.[000201] In some embodiments, a multi- specific antibody comprises variant CH3 domains that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Incorporation of such variant CH3 domains facilitates heterodimerization, e.g., of different antibodies to form multi- specific antibodies. Not limiting examples of such multi- specific antibody configurations are provided in International Patent Application Publication Number WO2022150785, “VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF”; published on July 14, 2022, the contents of which are incorporated herein by reference in their entirety.[000202] In some embodiments, a bispecific antibody comprises direct fusion or linking of different antigen- specific binding sites. In some embodiments, a bispecific antibody comprises immunoglobulin-derived heterodimerization domains to generate bispecific antibodies. For example, in some embodiments, a bispecific antibody can be formed by coexpression of two different heavy chains and two different light chains. In some embodiments, a bispecific antibody can be formed by co-expression of two different heavy chains and a common light chain. In some embodiments, fusion of two antibody-producing cell lines allows the combination of the heavy and light chains of two different antibodies, such that resulting bispecific antibodies comprise the heavy and light chain of the first antibody and the heavy and light chain of the second antibody. In some embodiments, heavy and light chain constant regions are of the same isotype. In some embodiments, heavy and light chain constant regions are of different isotype.[000203] In some embodiments, a bispecific antibody comprises variant heavy chains and / or light chains that force correct assembly between the two heavy chains and cognate heavy and light chains, or to facilitate purification of correctly assembled bispecificantibodies (See, e.g., Figures 3 and 4 and Table 1 in Brinkmann U and Kontermann EE, The making of bispecific antibodies, MAbs. 2017 Feb / Mar;9(2): 182-212). In some embodiments, a bispecific antibody is formed using the knobs-into-holes technique, e.g., to facilitate heterodimerization. The knobs-into-holes technique may be used, in some embodiments, to produce bispecific IgG molecules, trivalent Ig-like antibodies, bispecific Fc and CH3 fusion proteins, and other formats, as discussed in Ridgway JB, et al., 'Knobs-into- holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; Atwell S, et al., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, J Mol Biol 1997; 270:26-35; and Merchant AM, et al., An efficient route to human bispecific IgG, Nat Biotechnol 1998; 16:677-681, the entire contents of each of which are incorporated herein by reference in their entireties. [000204] In some embodiments, a bispecific antibody comprises an engineered CHI domain (first constant Ig domain of the heavy chain) that facilitates proper heavy chain-light chain pairing, e.g., in such co-expression system, such as is disclosed in International Patent Application Publication No.: W02021067404, “CHI DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME”, published on April 8, 2021, the contents of which are incorporated herein by reference.[000205] In some embodiments, a bispecific antibody comprises variant CHI domain that pairs e.g., preferentially pairs) with a particular variant CL domain. For example, in some embodiments, a bispecific antibody comprises a heavy chain comprising a variant CHI domain that preferentially pairs with a variant CLK or CLZ. domain. Not limiting examples of such bispecific antibody configurations are provided in International Patent Application Publication No.: WO2022150787, “VARIANT CHI DOMAINS AND VARIANT CL DOMAINS ENGINEERED FOR PREFERENTIAL CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME”, published on July 14, 2022, the contents of which are incorporated herein by reference in their entirety.[000206] In some embodiments, a bispecific antibody comprises variant CH3 domains that preferentially form CH3-CH3 heterodimers over CH3-CH3 homodimers. Incorporation of such variant CH3 domains facilitates heterodimerization, e.g., of different antibodies to form bispecific antibodies. Not limiting examples of such bispecific antibody configurations are provided in International Patent Application Publication No.: WO2022150785, “VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THESAME, AND METHODS OF MAKING THEREOF”; published on July 14, 2022, the contents of which are incorporated herein by reference in their entirety.[000207] In some embodiments, a bispecific antibody may be formed using nonimmunoglobulin heterodimerization modules to combine different antigen- specific binding sites in a non-covalent or covalent manner. For example, in some embodiments, a bispecific antibody is formed via a dock-and-lock method (DNL) utilizing heterodimeric assembly of the regulatory subunit of cAMP-dependent protein kinase (PKA) and the anchoring domains (AD) of A kinase anchor proteins (AKAPs). In some embodiments, a bispecific antibody may be formed using non-immunoglobulin heterodimerization modules to combine different antigen- specific binding sites, such as the barnase-barstar system, adapter / docking tag modules based on mutated RNase I fragments, and SNARE modules based on interaction of the three proteins syntaxin, synaptobrevin and SNAP25.IV. Pharmaceutical Composition[000208] The antibodies, as well as the encoding nucleic acids or nucleic acid sets, vectors comprising such, or host cells comprising the vectors, as described herein can be mixed with a pharmaceutically acceptable carrier (excipient) to form a pharmaceutical composition for use in treating a target disease. “Acceptable” means that the carrier must be compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. Pharmaceutically acceptable excipients (carriers) including buffers, which are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K. E. Hoover.[000209] The anti-KLK5 / KLK7 + IL- 13 bispecific antibody that comprises at least one antigen- specific binding site containing pharmaceutical composition disclosed herein may further comprise a suitable buffer agent. A buffer agent is a weak acid or base used to maintain the pH of a solution near a chosen value after the addition of another acid or base. In some examples, the buffer agent disclosed herein can be a buffer agent capable of maintaining physiological pH despite changes in carbon dioxide concentration (produced by cellular respiration). Exemplary buffer agents include, but are not limited to, a HEPES (4-(2- hydroxyethyl)-l -piperazineethanesulfonic acid) buffer, Dulbecco's phosphate-buffered saline (DPBS) buffer, or Phosphate-buffered Saline (PBS) buffer. Such buffers may comprise disodium hydrogen phosphate and sodium chloride, or potassium dihydrogen phosphate and potassium chloride.[000210] The pharmaceutical composition described herein comprises one or more suitable salts. A salt is an ionic compound that can be formed by the neutralization reaction of an acid and a base. (Skoog, D.A; West, D.M.; Holler, J.F.; Crouch, S.R. (2004). “Chapters 14-16”. Fundamentals of Analytical Chemistry (8th ed.)). Salts are composed of related numbers of cations (positively charged ions) and anions (negative ions) so that the product is electrically neutral (without a net charge).[000211] In some embodiments, the pharmaceutical compositions can comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions. (Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K. E. Hoover). In some embodiments, the pharmaceutical composition can be formulated for intravenous injection. In some embodiments, the pharmaceutical composition can be formulated for subcutaneous injection. [000212] The pharmaceutical compositions to be used for in vivo administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes. Therapeutic antibody compositions are generally placed into a container having a sterile access port, for example, an intravenous or subcutaneous solution bag or vial having a stopper pierceable by a hypodermic injection needle.V. Methods of Use[000213] In certain aspects, the disclosure provides methods and related compositions for treating conditions associated with KLK5 and KLK7 related dysregulation, including, for example, Netherton Syndrome, atopic dermatitis (with and without filaggrin mutations), eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), dry skin, asthma (e.g., KLK5 related asthma specifically), ichthyosis vulgaris, and skin itch. In some embodiments, Th2 cytokines (e.g., IL-13, IL-4, IL-5, IL-6, IL-9, IL-31, and IL-17E (IL- 25)) are also involved in conditions with KLK5 and KLK7 dysregulation described herein. Accordingly, in some aspects, the disclosure provides methods and compositions for inhibition of KLK5 and KLK7, and IL- 13. In some embodiments, the disclosure provides a bispecific antibody for inhibition of KLK5 and KLK7, and IL- 13 for treating the conditions provided herein.[000214] Aspects of the disclosure relate to methods and compositions (e.g., anti- KLK5 / KLK7 dual inhibitor antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful promoting proper barrier function (e.g., epidermal barrier function). Hyperactivekallikrein 5 / 7 causes both genetic and spontaneous disruption of epidermal barrier function and is associated with related disorders, such as Netherton syndrome, eosinophilic esophagitis, atopic dermatitis. Accordingly, in some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of restoring the epithelial barrier in a subject in need thereof. In other aspects, methods are provided for addressing one or more aspects of altered barrier function. For example, in some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti- KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing dermal infiltrates in a subject in need thereof. In some embodiments, methods provided herein comprise administering an effective amount of one or more anti- KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing epithelium inflammation in a subject in need thereof. In some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti- KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing epithelium permeability in a subject in need thereof. In some embodiments, methods provided herein comprise administering an effective amount of anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing parakeratosis in a subject in need thereof. In some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing skin inflammatory cytokines in a subject in need thereof. In some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of reducing transepidermal water loss in a subject in need thereof.[000215] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating atopic dermatitis. Atopic dermatitis (AD), also known as eczema, is a common chronic pruritic inflammatory skin disease. In some embodiments, atopic dermatitis begins in a subject in infancy or early childhood (e.g., at or about 2 years of age). Accordingly, in some embodiments, methods provided herein are useful for treating subjects having atopicdermatitis who are 2 year of age or older. Atopic dermatitis may be associated with elevations of the total serum IgE concentration. According, in some embodiments, methods provided herein are useful for treating subjects having atopic dermatitis with elevated levels of total serum IgE concentrations (e.g., compared with normal IgE levels in subjects who do not have atopic dermatitis or related conditions). In some embodiments, atopic dermatitis is associated with a chronic relapsing form of skin inflammation, a disturbance of epidermal barrier function (e.g., that culminates in dry skin), and / or IgE-mediated sensitization to allergens, such as food and environmental allergens. Accordingly, in some embodiments, methods of treating a subject having atopic dermatitis are provided herein that comprise administering an effective amount of anti-KLK5 / KLK7 antibodies or one or more anti- KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject. Further, in some embodiments, subjects to be treated exhibit a chronic relapsing form of skin inflammation, a disturbance of epidermal barrier function, and / or IgE-mediated sensitization to allergens.[000216] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein to a subject having AD reduces ear thickness in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the parental anti-IL-13 or anti-IL-13R antibody).[000217] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein to a subject having AD reduces skin erythema / hemorrhage in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the parental anti- IL-13 or anti-IL-13R antibody).[000218] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein to a subject having AD reduces skin excoriation / erosion in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the parental anti-IL-13 or anti-IL-13R antibody).[000219] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein to a subject having AD reduces skin edema in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the parental anti-IL-13 or anti-IL-13R antibody). [000220] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13 bispecific antibody described herein to a subject having AD reduces skin scaling / dryness in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the anti-IL-13 or anti-IL-13R antibody).[000221] In some embodiments, administration of an anti-KLK5 / KLK7 + IL- 13bispecific antibody described herein to a subject having AD reduces skin lesion severity in the subject by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 100%) relative to a subject receiving either one of the parental antibodies of the bispecific antibody (e.g., the parental anti-KLK5 / KLK7 antibody or the parental anti-IL-13 or anti-IL-13R antibody). The severity of skin lesions (four parameters: erythema / hemorrhage, edema, excoriation / erosion, and scaling / dryness) is evaluated by signs on the ears, neck and dorsal skin. The total clinical skin severity score is defined as the sum of the individual scores (0: None; 1: Mild; 2: Moderate; 3: Severe).[000222] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating subjects having Netherton syndrome. In some embodiments, methods of treating a subject having Netherton syndrome are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti- KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject. Netherton syndrome is a rare and severe autosomal recessive skin disorder. In some embodiments, Netherton syndrome is associated with congenital erythroderma, a specific hair- shaft abnormality, and / or atopic manifestations with high IgE levels (e.g., compared with normal IgE levels in subjects who do not have Netherton Syndrome or related conditions). In some embodiments, subjects having Netherton syndrome exhibit atopic manifestations include eczema-like rashes, atopic dermatitis, pruritus, hay fever, angioedema, urticaria, high levels of IgE in the serum, and / orhypereosinophilia. In some embodiments, Netherton syndrome is caused by mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor lymphoepithelial Kazal-type-related inhibitor. In some embodiments, absence of this protease inhibitor causes stratum corneum detachment secondary to epidermal proteases hyperactivity. Accordingly, in some embodiments, methods provided herein comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies provided herein to a subject for purposes of ameliorating one or more aspects or symptoms (e.g., atopic manifestations, e.g., skin rash scaling, stratum corneum detachment) associated with Netherton Syndrome. [000223] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating eosinophilic esophagitis. In some embodiments, symptoms of eosinophilic esophagitis include difficulty feeding, failure to thrive, vomiting, epigastric or chest pain, dysphagia, and food impaction. In some embodiments, subjects having eosinophilic esophagitis are young males with a relatively high predisposition to atopic disease. In some embodiments, subjects having eosinophilic esophagitis are diagnosed by endoscopy and / or biopsy findings of isolated eosinophils in the esophagus. In some embodiments, eosinophilic esophagitis is defined histologically by the presence of proliferative changes, which, in some embodiments, includes thickening of the basal epithelial layer and / or elongation of papillae, a minimum of 24 eosinophils per high-power field in the distal esophagus, and / or the absence of eosinophilia in any other evaluated intestinal segment. In some embodiments, subjects having eosinophilic esophagitis exhibit low levels or lack of certain serine protease inhibitors belonging to the lympho-epithelial Kazal-type inhibitor protein family, such as SPINK7, e.g., in esophageal biopsies. In some embodiments, eosinophilic esophagitis is differentiated from reflux esophagitis on the basis of the magnitude of mucosal eosinophilia and lack of response to acid suppression. In some embodiments, methods of treating a subject having eosinophilic esophagitis are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject.[000224] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating prurigo nodularis. Prurigo nodularis is a chronic inflammatory skin disease where an extremely itchy, symmetrically distributed rash appears most commonly on the arms, legs, the upper back and / or the abdomen. In some embodiments, prurigo nodularis appears on itsown. However, in some embodiments, prurigo nodularis is associated with other skin diseases or medical conditions, such as cancer, diabetes, chronic kidney disease or AIDS. In some embodiments, altered function of the immune system and nerves in the skin is believed to be associated with heightened sensations of itchiness (pruritus) that leads to frequent scratching; whereby such frequent scratching and picking of the skin contributes to further lesion thickening and formation. Accordingly, in some embodiments, methods of treating a subject having prurigo nodularis are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject.[000225] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating chronic pruritis. In some embodiments, chronic pruritus is associated with an itch lasting greater than 6 weeks (e.g., up 3 months, up 6 months, up to 1 year, or more). In some embodiments, chronic pruritus arises in association with potentially unrelated diseases, including chronic kidney disease, hepatobiliary disease, and neuropathic entities such as brachioradial pruritus and notalgia paresthetica. In some embodiments, chronic pruritus of unknown origin (CPUO) is established when no underlying origin for pruritus can be determined. In some embodiments, chronic pruritus is associated with severe itch and significant scratch lesions, in some embodiments, methods of treating a subject having chronic pruritis, including CPUO, are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti- KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject.[000226] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating ichthyosis vulgaris. In some embodiments, ichthyosis vulgaris is caused by heterozygous mutation in the filaggrin gene. In some embodiments, subjects with homozygous or compound heterozygous mutations in this gene have a more severe phenotype. In some embodiments, ichthyosis vulgaris is characterized histologically by absent or reduced keratohyalin granules in the epidermis and mild hyperkeratosis. Keratohyalin contains a histidine-rich protein which is the precursor form (profilaggrin) of filaggrin, a keratin filament-aggregating protein. In some embodiments, profilaggrin and filaggrin are reduced or absent in subjects having ichthyosis vulgaris. In some embodiments, ichthyosis vulgaris comprises palmar hyperlinearity, keratosis pilaris, and a fine scale that is most prominent over the lower abdomen, arms, and legs. In some embodiments, a subjectmay exhibit prominent scaling. In some embodiments, a subject may exhibit palmar hyperlinearity, keratosis pilaris, and, in some cases, fine scaling. Accordingly, in some embodiments, methods of treating a subject having ichthyosis vulgaris or one or more symptoms or phenotypic characteristics thereof are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject.[000227] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating psoriasis. Psoriasis (or psoriasis vulgaris) is a chronic inflammatory dermatosis. In some embodiments, psoriasis is characterized by red, scaly skin patches that may be found on the scalp, elbows, and / or knees of a subject. In some embodiments, psoriasis is associated with severe arthritis in a subject. In some embodiments, psoriasis associated lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. In some embodiments, subject’s experience onset of psoriasis between 15 and 30 years of age. In some embodiments, psoriatic lesions are characterized by skin induration, scaling, and / or erythema, which may be accompanied by histologic evidence of inflammation, abnormal keratinocyte proliferation / terminal differentiation, and / or dermal angiogenesis. In some embodiments, psoriatic inflammatory infiltrates, which may be pronounced at the dermal-epidermal junction, comprise activated T cells and antigen- presenting cells (APCs). In some embodiments, presence of activated T cells and APCs in such infiltrates precede development of epidermal hyperproliferation. In some embodiments, increased levels of inflammatory cytokines are detectable in lesional psoriatic epidermis, which may result in the potentiation of T-cell activation as well as hyperproliferation and accelerated differentiation of keratinocytes. In some embodiments, methods of treating a subject having psoriasis are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject. In some embodiments, subjects are treated prior to development of epidermal hyperproliferation. However, in some embodiments, subjects are treated after development of epidermal hyperproliferation and accelerated differentiation of keratinocytes.[000228] Further aspects of the disclosure relate to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) useful for treating rosacea. Rosacea is an inflammatory disease characterized by erythema, papulopustules, and / or telangiectasia. In some embodiments, subjects having rosacea expressabnormally high levels of cathelicidin in their facial skin. In some embodiments, proteolytically processed forms of cathelicidin peptides found in rosacea are different from those present in normal subjects. In some embodiments, methods of treating a subject having rosacea are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies to the subject.[000229] Further aspects of the disclosure relate to methods of treating a subject having asthma are provided herein that comprise administering an effective amount of one or more antibodies disclosed herein (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) to the subject. In some embodiments, methods of treating a subject having asthma are provided herein that comprise administering an effective amount of one or more anti-KLK5 / KLK7 antibodies or one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibodies. In some embodiments, the subject has asthma (e.g., a subject to be treated with a KLK5 targeting antibody provided herein). In some embodiments, the asthma is selected from: allergic asthma, aspirin sensitive / exacerbated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids or other chronic asthma controller medications, atopic asthma, bronchial obstruction associated asthma, pathogenesis-related asthma, chronic asthma, corticosteroid naive asthma, corticosteroid refractory asthma, corticosteroid resistant asthma, eosinophil-high asthma, eosinophilic asthma, eosinophil-low asthma, exercise-induced asthma, mild asthma, moderate to severe asthma, Netherton Syndrome asthma, newly diagnosed and / or untreated asthma, non-allergic asthma, non-Th2-driven asthma, periostin- high asthma, periostin-low asthma, Th2-low asthma, Type 2 (T2)-driven asthma, and Type 2 low inflammation asthma. In some embodiments, the subject has atopic asthma or allergic asthma. In some embodiments, the subject has aspirin- sensitive or aspirin-exacerbated asthma. In some embodiments, the subject has asthma associated with a non-steroidial antiinflammatory drug (NSAID). Accordingly, in some embodiments, the subject has asthma that was triggered by aspirin or similar NSAID (e.g., recently ingested aspirin or similar NSAID). In some embodiments, the subject has bronchial spasms that may or may not be characterized as asthma. For example, in some embodiments, the subject has exercise- induced bronchial spasms.[000230] In some embodiments, the subject has eosinophilic asthma. In some embodiments, the subject has an eosinophilic inflammation positive (EIP) asthma. In some embodiments, the subject has eosinophilic inflammation negative (EIN) asthma. In some embodiments, the subject has eosinophil-high asthma (e.g., at least about any of 150, 200,250, 300, 350 or 400 eosinophil counts / ml blood). In some embodiments, the subject has eosinophil-low asthma (e.g., less than about 150 eosinophil counts / pl blood or less than about 100 eosinophil counts / pl blood). These and further examples of asthma related conditions treatable using compositions provided herein (e.g., anti-KLK5 / KLK7 antibodies) are disclosed in WO2015 / 061441, METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS, published on April 30, 2015, the relevant contents of which are incorporated herein by reference.[000231] In some embodiments, the subject has exercise-induced asthma, intermittent or exercise-induced, mild asthma, mild or corticosteroid naive asthma, moderate to severe asthma, Netherton Syndrome asthma, newly diagnosed asthma untreated asthma, or severe asthma. In some embodiments, the subject has asthma not previously requiring or involving use (e.g., chronic use) of inhaled topical or systemic steroids to control or manage symptoms (e.g., symptoms such as cough, wheezing, shortness of breath / breathlessness, and chest pain) [000232] In some embodiments, the subject has periostin-low asthma (e.g., having periostin level less than about 20 ng / mL serum). In some embodiments, the subject has periostin-high asthma (e.g., having periostin level at least about any of 20 ng / mL, 25 ng / mL, or 50 ng / mL serum). In some embodiments, the subject has non-allergic asthma (e.g., which may or may not be triggered by infection, e.g., with a respiratory virus (e.g., influenza, coronavirus, parainfluenza, rhinovirus, human metapneumovirus, and respiratory syncytial virus) or inhaled irritant (air pollutant, smog, combustion particles (e.g., diesel particles), volatile chemicals, gases indoors or outdoors) or by relatively cold dry air. In some embodiments, the subject has asthma due to acute or chronic primary or second-hand exposure to smoke (cigarettes, cigars, pipes, or other combustion products) or as a result of inhaling or vaping (nicotine, cannabis or other similar substances). In some embodiments, the subject has persistent chronic severe asthma with acute events of worsening symptoms (exacerbations or flares) that can be life threatening.[000233] In some embodiments, the subject has a T helper lymphocyte type 2 (Th2) or type 2 (Th2) high asthmatic condition. In some embodiments, the subject has Th2 induced asthma. For example, in some embodiments, Th2 cells and / or their secreted effector molecules mediate immune response to allergens and are triggered by exposure to specific allergens leading to allergic asthma in a subject. In some embodiments, a subject has activated Th2 cell-mediated asthma, which may be caused in part by the secretion of interleukins, e.g., IL-13. Accordingly, in some embodiments, KLK5 antibodies (or other antibodies) may be combined separately or in a multi- specific antibody format with one ormore antibodies targeting IL- 13 as well as targets associated with allergy such as IgE. Examples of such antibodies for the treatment of asthma include, but are not limited to, omalizumab (XOLAIR®) (targeting soluble IgE); lebrikizumab (targeting IL- 13); and quilizumab (targeting membrane-bound IgE).[000234] Still, in other embodiments, antibodies as described herein are used to treat, but are not limited to the following, inflammatory disorders, infectious diseases, allergic diseases, and autoimmune disorders. In some embodiments, the inflammatory disorders are selected from but not limited to, rosacea, prurigo nodularis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, hidradenitis suppurativa, and uveitis or one or more barrier function related symptoms thereof. In some embodiments, the allergic diseases are selected from but not limited to, eczema, atopic dermatitis, asthma, sinusitis, and eosinophilic esophagitis. In some embodiments, the autoimmune diseases are selected from but not limited to, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, Behcet's disease, and plaque psoriasis or one or more barrier function related symptoms thereof.[000235] Determination of whether an amount of the antibody (e.g., anti-KLK5 / KLK7 antibody, or anti-KLK5 / KLK7 + IL- 13 bispecific antibody) achieved the therapeutic effect would be evident to one of skill in the art based on the teachings provided herein. Effective amounts vary, as recognized by those skilled in the art, depending on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. The particular dosage regimen, i.e., dose, timing and repetition, used in the method described herein will depend on the particular subject and that subject's medical history, as discussed herein.[000236] Empirical considerations, such as time to maximum effect, the half-life, and / or time above a specific concentration generally will contribute to the determination of the dosage. For example, antibodies that are compatible with the human immune system, such as humanized antibodies or fully human antibodies, may be used to prolong half-life of the antibody and to prevent the antibody being attacked by the host's immune system. Other reasons for dose-adjusting include differences in pharmacokinetics or pharmacodynamic response driven by sex, age, individual response, polymorphisms on the antibody target and / or receptors involved in antibody clearance. Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and / or suppression and / or amelioration and / or delay of a targetdisease / disorder. Alternatively, sustained continuous release formulations of an antibody may be appropriate. Various formulations and devices for achieving sustained release are known in the art.[000237] Dosing frequencies may vary in accordance with the claimed methods. In some embodiments, a composition may be administered once. In some embodiments, a composition will be administered on multiple occasions. In some embodiments, dosing frequency is every week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, or every 10 weeks; or once every month, every 2 months, or every 3 months, or longer. In some embodiments, a composition will be administered daily, biweekly, weekly, bimonthly, monthly, or at any time interval that provides suitable (e.g., maximal) efficacy while minimizing safety risks to the subject. Generally, the efficacy and the treatment and safety risks may be monitored throughout the course of treatment.[000238] In some embodiments, a subject may be administered a composition provided herein (e.g., an anti-KLK5 / KLK7 antibody or a anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) at one or more intervals during a set period of time. In some cases, periods of time during which a subject is administered a composition at one or more intervals may be separated by periods of time in which the subject is not administered the composition. In some embodiments, the relative durations of respective periods of time may depend on the subject’s response to treatment or severity of disease or both and / or may be determined based on the judgment of a treating physician.[000239] In some embodiments, an antibody can be administered parenterally. For example, a parenterally administered composition may be administered topically, transmucosally, by subcutaneous, intracutaneous, intravenous, intraperitoneal, intratumor, intramuscular, intraarticular, intraarterial, or infusion techniques.[000240] In some embodiments, an antibody (e.g., an anti-KLK5 / KLK7 antibody or an anti-KLK5 / KLK7 + IL- 13 bispecific antibody) is administered intravenously. In some embodiments, an antibody (e.g., an anti-KLK5 / KLK7 antibody or an anti-KLK5 / KLK7 + IL- 13 bispecific antibody) is administered subcutaneously or topically.[000241] For intravenous injection, water soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing the antibody and a physiologically acceptable excipient is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline. Ringer’s solution or other suitable excipients. Other injectable compositions may contain various carriers such as vegetable oils,dimethylactamide, dimethyformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). In some cases, preparations, e.g., a sterile formulation of a suitable soluble salt form of the antibody, can be dissolved and administered in a pharmaceutical excipient such as Water-for- Injection, 0.9% saline, or 5% glucose solution.[000242] In one embodiment, an antibody is administered via site- specific or targeted local delivery techniques. Examples of site-specific or targeted local delivery techniques include various implantable, transdermal, or transmucosal depot sources of the antibody or local delivery systems.[000243] An anti-KLK5 / KLK7 antibody or an one or more anti-KLK5 / KLK7 + IL- 13 bispecific antibody and treatment methods involving such as described in the present disclosure may be utilized in combination with other types of therapy for the target disease or disorder disclosed herein. In this context, an antibody composition and a therapeutic agent may be given either simultaneously or sequentially. Such therapies can be administered simultaneously or sequentially (in any order) with the treatment according to the present disclosure.[000244] Accordingly, aspects of the disclosure related to methods and compositions (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies). In some embodiments, antibodies as described herein, can be administered as a combination therapy (concomitantly or sequentially, e.g., over time). In some embodiments, the combination therapy comprises administering one or more of the antibodies as described herein (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) and at least one additional therapeutic agent (e.g., one, two, three, four, five, six, or seven therapeutic agents). In some embodiments, one or more of the antibodies as described herein and at least one additional therapeutic agent (e.g., one, two, three, four, five, six, or seven therapeutic agents) are administered together. In some embodiments, one or more of the antibodies as described herein and at least one additional therapeutic agent (e.g., one, two, three, four, five, six, or seven therapeutic agents) are administered separately.[000245] In some embodiments, the additional therapeutic agent is an anti-inflammatory agent. In some embodiments, the anti-inflammatory agent is selected from but is not limited to, low-dose antibiotics, steroids, corticosteroids, tacrolimus, anti-IL4R antibodies (e.g., dupilumab), anti-IL-13 antibodies, TNE inhibitors (e.g., anti-TNE), IL-12 / 23 inhibitors, IL-17 inhibitors, and IL-4 receptor inhibitors, doxycycline, methotrexate, prednisone, cyclosporine, mycophenolate mofetil, dupilumab, certolizumab pegol, etanercept, adalimumab, infliximab,golimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, abatacept, tidrakizumab- asmn, risankisumab-rzaa, and guselkumab. In some embodiments, the anti-inflammatory agent is administered orally. In some embodiments, the anti-inflammatory agent is administered topically. In some embodiments, the anti-inflammatory agent is administered via injection (e.g., intravenous, subcutaneous, or intramuscular).[000246] In some embodiments the therapeutic combination comprises one or more of the antibodies as described herein (e.g., anti-KLK5 / KLK7 antibodies or anti-KLK5 / KLK7 + IL- 13 bispecific antibodies) delivered with one or more additional antibodies or fragments thereof (e.g., one, two, three, four, five, six, or seven antibodies). In some embodiments, the therapeutic combination comprising one or more of the antibodies as described herein and one or more additional antibodies or fragments thereof (e.g., one, two, three, four, five, six, or seven antibodies) are delivered separately. In some embodiments, the therapeutic combination comprising one or more of the antibodies as described herein and one or more additional antibodies or fragments thereof (e.g., one, two, three, four, five, six, or seven antibodies) are delivered together.[000247] In some embodiments, the therapeutic combination comprising one or more of the antibodies as described herein and one or more additional antibodies or fragment thereof (e.g., one, two, three, four, five, six, or seven antibodies) is as a multi- specific antibody combination. In some embodiments, the multi- specific antibody combination comprises a KLK5 / KLK7 antigen-specific binding site, and one or more additional distinct antigenspecific binding sites from one or more additional antibodies. In some embodiments, a multispecific antibody comprises direct fusion or linking of different antigen- specific binding sites. In some embodiments, the additional antibodies or fragments thereof are selected from but not limited to, an anti-IL4R antibody, an anti-IL-13 antibodies, an anti-TNF antibody, an anti-IL- 12 / 23 antibody, an anti-IL-17 antibody, doxycycline, dupilumab, certolizumab pegol, etanercept, adalimumab, infliximab, golimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, abatacept, tildrakizumab- asmn, risankizumab-rzaa, and / or guselkumab.[000248] In some embodiments, in a non-limiting example, in the treatment of rosacea, additional therapeutics could be selected from a topically administered steroid; oral administration of methotrexate; oral administration of cyclosporine; and / or administration of a TNF inhibitor. In some embodiments, in a non-limiting example, in the treatment of atopic dermatitis, additional therapeutics could be selected from subcutaneous administration of dupilumab, and / or topical administration of a steroid.[000249] Any of the anti-KLK5 / KLK7 antibodies disclosed herein can also be used fordetecting presence of KLK5 and / or KLK7 in vitro or in vivo. Results obtained from such detection methods can be used for diagnostic purposes (e.g., diagnosing diseases associated with KLK5 and / or KLK7) or for scientific research purposes (e.g., identifying new KLK5 secreting cell types, studying bioactivity and / or regulation of secreted KLK5 and / or KLK7). For assay uses such as diagnostic uses, an anti-KLK5 / KLK7 antibody or anti-KLK5 / KLK7 + IL- 13 bispecific antibody as described herein may be conjugated with a detectable label (e.g., an imaging agent such as a contrast agent) for detecting presence of KLK5 and / or KLK7, either in vivo or in vitro.[000250] As used herein, “conjugated” or “attached” means two entities are associated, preferably with sufficient affinity that the therapeutic / diagnostic benefit of the association between the two entities is realized. The association between the two entities can be either direct or via a linker, such as a polymer linker. Conjugated or attached can include covalent or noncovalent bonding as well as other forms of association, such as entrapment, e.g., of one entity on or within the other, or of either or both entities on or within a third entity, such as a micelle.[000251] In other embodiments, an anti-KLK5 / KLK7 antibody as described herein can be attached to a detectable label, which is a compound that is capable of releasing a detectable signal, either directly or indirectly, such that the aptamer can be detected, measured, and / or qualified, in vitro or in vivo. Examples of such “detectable labels" are intended to include, but are not limited to, fluorescent labels, chemiluminescent labels, colorimetric labels, enzymatic markers, radioactive isotopes, and affinity tags such as biotin. Such labels can be conjugated to the aptamer, directly or indirectly, by conventional methods. [000252] The reporting agent can also be a dye, e.g., a fluorophore, which is useful in detecting a disease mediated by KLK5 and / or KLK7 expressing cells in tissue samples respectively.[000253] To perform a diagnostic assay in vitro, an anti-KLK5 / KLK7 antibody can be brought in contact with a sample suspected of containing KLK5 and / or KLK7, e.g., KLK5 expressing cells or soluble KLK5 in disease microenvironment. The antibody and the sample may be incubated under suitable conditions for a suitable period to allow for binding of the antibody to the KLK5 antigen. Such an interaction can then be detected via routine methods, e.g., ELISA, histological staining or FACS. To perform a diagnostic assay in vivo, a suitable amount of anti-KLK5 / KLK7 antibodies, conjugated with a label (e.g., an imaging agent or a contrast agent), can be administered to a subject in need of the examination. Presence of the labeled antibody can be detected based on the signal released from the label by routinemethods.[000254] To perform scientific research assays, an anti-KLK5 / KLK7 antibody can be used to study bioactivity of KLK5 and / or KLK7, detect the presence of KLK5 and / or KLK7 intracellularly or extracellularly, and or regulating the effect of KLK5. For example, a suitable amount of anti-KLK5 / KLK7 can be brought in contact with a sample (e.g., a new cell type that is not previously identified as KLK5 and / or KLK7 producing cells) suspected of producing KLK5 and / or KLK7. The cells are permeabilized prior to contacting the anti- KLK5 / KLK7 antibody. The antibody and the sample may be incubated under suitable conditions for a suitable period to allow for binding of the antibody to the KLK5 antigen. Such an interaction can then be detected via routine methods, e.g., ELISA, histological staining or FACS.VI. Kits for Therapeutic and Diagnostic Applications[000255] The present disclosure also provides kits for the therapeutic or diagnostic applications as disclosed herein. Such kits can include one or more containers comprising an antibody, e.g., any of those described herein.[000256] In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise a description of administration of the antibody to treat, delay the onset, or alleviate a target disease as those described herein. The kit may further comprise a description of selecting an individual suitable for treatment based on identifying whether that individual has the target disease. In still other embodiments, the instructions comprise a description of administering an antibody to an individual at risk of the target disease.[000257] The instructions relating to the use of an antibody described generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine- readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.[000258] The label or package insert indicates that the composition is used for treating, delaying the onset and / or alleviating a disease or disorder. Instructions may be provided for practicing any of the methods described herein.[000259] The kits of this invention are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like.[000260] Also contemplated are packages for use in combination with a specific device, such as an infusion device, such as a minipump. A kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody as those described herein.[000261] Kits may optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container. In some embodiments, the invention provides articles of manufacture comprising contents of the kits described above.[000262] Also provided herein are kits for use in detecting the target protein (e.g., KLK5 and / or KLK7, or KLK5 and KLK7 plus IL-13) in a sample. Such a kit may comprise any of the antibodies described herein. In some instances, the antibody can be conjugated with a detectable label as those described herein. As used herein, “conjugated” or “attached” means two entities are associated, preferably with sufficient affinity that the therapeutic / diagnostic benefit of the association between the two entities is realized. The association between the two entities can be either direct or via a linker, such as a polymer linker. Conjugated or attached can include covalent or noncovalent bonding as well as other forms of association, such as entrapment, e.g., of one entity on or within the other, or of either or both entities on or within a third entity, such as a micelle.[000263] Alternatively or in addition, the kit may comprise a secondary antibody capable of binding to an antibody described herein. The kit may further comprise instructions for using the antibody for detecting the target protein (e.g., KLK5 and / or KLK7, or KLK5 and KLK7 plus IL- 13).EXAMPLESExample 1: Generation and Selection of Dual Inhibitor Anti-KLK5 / KLK7 Antibodies(i) Affinity[000264] Antibody binding kinetic experiments via Biacore were performed to screenfor anti-KLK5 / KLK7 antibodies having high affinity to the respective targets. All screening assays were performed at 25 C. The running buffer used was 20 mM HEPES, 300 mM NaCl, 0.01% Tween-20, pH 7.5. Antibodies (1 ug / mL) were captured on Fc2-4 of a Series S ProteinA Sensor Chip (Cytiva) flowing at 10 ul / mL for 30 s. Kinetics measurements were made in single-cycle kinetics mode with a series of 4-5 concentrations with top concentration of 25-100 nM and serial dilution 4-fold. Contact time was typically 300 s and dissociation time ranged from 1800-3600 s. Flow rate of 30 ul / mL was typically used. The sensor chip was regenerated with 10 mM glycine, pH 1.5 with a contact time of 30 s flowing at 50 ul / mL. The results show that dual inhibitor antibodies described in Table la showed binding specificity to both KLK5 and KLK7. A summary of the binding kinetics for the anti-KLK5 antibodies is provided below in Table 4.Table 4 Anti-KLK5 / KLK7 Antibody Affinity and Potency(ii) Protease inhibition assay[000265] To evaluate the ability of antibodies described in Table la to inhibit KLK5 and / or KLK7 protease activity respectfully, 1.5nM of human or mouse KLK5 or 0.5nM of human or mouse KLK7 were prepared in assay buffer (.I M NaH2PO4 pH=7.5 for KLK5 and 50 mM Tris, 150 mM NaCl, pH 7.5 for KLK7). Antibodies diluted in PBS to testing concentrations were added. Substrate was then added (50uM BOC-Val-Pro-Arg-AMC for KLK5 and 30uM KHLF-AMC for KLK7). Fluorescence signal was then measured every min for 30min at room temperature.[000266] The results show that the anti-KEK5 / KEK7 antibodies are capable ofinhibiting KLK5 and KLK7 protease activity as described in Table 4.Example 2: Generation of Anti-KLK5 / KLK7 + Th2 Targeting Bispecific Antibodies[000267] Experiments were performed that show inhibiting KLK5 / KLK7 using a dual inhibitor anti-KLK5 / KLK7 antibody had beneficial effects beyond an anti-IL4R antibody in Nc / Nga mouse model. Murine atopic dermatitis was induced in Nc / Nga mice (a strain with an intrinsic barrier defect due to reduced expression of ceramides) by topical application of House Dust Mite (HDM) allergen. 8-10 week old animals receive Biostir- AD ointment (120 mg / mouse), which contains mite allergens derived from Dermatophagoides farina, onto both ears and dorsal skin regions (including the neck), twice a week for two weeks, a total of 480 mg Biostir- AD per mouse. A 150 pL SDS was applied at 2 hours before the Biostir- AD application from the second treatment (Day 4). Vehicle or test article (Control IgG, KLK5- KLK7-Dual Ab4, the KLK5 / 7 inhibitor, or an anti-IL-4R inhibitor antibody) were injected at 30mg / kg intraperitoneally (IP) 3 times / week starting on day -6 for a total of 9 doses. The anti- IL-4R inhibitor antibody inhibits IL-4 signaling. The reference compound, tacrolimus ointment, is applied topically (TOP) once daily (QD) starting on Day -6 for a total of 21 days (QD x 21), applied at one (1) hr after Biostir-AD application on Biostir-AD challenge days. Model was evaluated for macroscopic skin lesion evaluation and ear thickness measurement on Day 15. Ear thickness is measured with a Dyer model micrometer gauge. The severity of skin lesions (four parameters: erythema / hemorrhage, edema, excoriation / erosion, and scaling / dryness) is evaluated by signs on the ears, neck and dorsal skin. The total clinical skin severity score is defined as the sum of the individual scores (0: None; 1: Mild; 2: Moderate; 3: Severe).[000268] The results showed that inhibiting KLK5 / KLK7 had enhanced effects in reducing ear thickness and clinical skin score compared with an anti-IL4R antibody.[000269] Accordingly, it is advantageous to produce bispecific antibodies that inhibit KLK5 / KLK7 activity and Th2 signaling in a single molecule. For example, bispecific antibodies with one arm having the antigen- specific binding site of an anti-KLK5 / KLK7 antibody as described in Table la and another arm having the antigen- specific binding site of a Th2 targeting antibody as described in Table 2 are suitable for inhibiting KLK5 / KLK7 and Th2 signaling via a single molecule.[000270] In one example, a bispecific antibody that inhibits KLK5 / KLK7 and IL- 13 was constructed with one arm having an antigen binding site targeting KLK5 / KLK7 derivedfrom KLK5 / KLK7-Dual-Ab4, and another arm having an antigen binding site of an anti-IL- 13 antibody comprising a VH having the amino acid sequence of SEQ ID NO: 32, and a VL having the amino acid sequence of SEQ ID NO: 33 (referred to as K13-0004). Binding affinity of the anti-KLK5 / KLK7 + IL- 13 bispecific antibody was assessed and compared to monospecific monoclonal antibodies having the same antigen binding sites for the respective antigens, as shown in Tables 5 and 7, demonstrating that such bispecific antibodies inhibit both pathways in a single molecule (see also FIGs. 4A-4D). The monospecific monoclonal antibodies are bivalent to the respective antigens. The bispecific antibody is monovalent to each antigen.Table 5 Anti-KLK5 / KLK7 + IL-13 Bispecific Antibody Affinity and Antibody (KD)Table 7 Anti-KLK5 / KLK7 + IL-13 Binding Antibody Affinity and Potency (IC50)[000271] FIGs. 4A-4C demonstrate KD data corresponding to Tables 5 and 7 of the anti- KLK5 / KLK7 + IL- 13 bispecific antibody binding to KLK5 (FIG. 4A), KLK7 (FIG. 4B), and IL13 (FIG. 4C). Binding was performed by capturing bispecific antibodies (1 ug / mL) on a Protein A chip surface. The flow rate during the capture step was 10 uL / min for 30 seconds. Then, either hKLK5, hKLK7, or hIL-13 were applied to the chip in varying concentrations using single-cycle kinetics format. Both hKLK5 and hKLK7 concentrations included 0.156, 0.625, 2.5, 10, and 40 nM. hIL-13 concentrations included 0.39, 1.56, 6.25, 25, and 100 nM. Flow rate during sample injection was 50 uL / min with association times of 300 seconds and a dissociation time of 3600 seconds. Regeneration of the chip was performed using 10 mMglycine at pH 1.5. Flow rate during the regeneration step was 50 uL / min for 30 seconds. The anti-KLK5 / KLK7 + IL- 13 bispecific antibody bound all targets with sub-nanomolar affinity. [000272] To evaluate the ability of bispecific antibodies to inhibit hKLK5 and hKLK7 protease activity, 1.5 nM of hKLK5 or hKLK7 was prepared in assay buffer (0.1M Tris-HCl, 0.1% (v / v) Triton X-100, pH 8.3). Antibodies diluted in assay buffer to testing concentrations were added and incubated with protease for 15 minutes. Substrate was then added (500 uM BOC-Val-Pro-Arg-AMC for hKLK5 and 50 uM KHLF-AMC for hKLK7). Fluorescence signal was then measured every minute for 1 hour at room temperature. The anti- KLK5 / KLK7 + IL- 13 bispecific antibody inhibited KLK5, KLK7, and IL- 13 as well as an anti-KLK5 / KLK7 dual antibody (KLK5 and KLK7, FIGs. 4D-4G) or an anti-IL13 and anti- IL4 antibody (IL- 13, FIG. 4H), indicating that configuring an anti-KLK5 / KLK7 antibody as a bispecific antibody does not interfere with the anti-KLK5 / KLK7 activity of the anti- KLK5 / KLK7 dual antibody or the anti-IL-13 antibody. The concentration of periostin, an extracellular matrix protein (ECM) that is increased in some allergic disease, was decreased to a comparable level following treatment with an anti-KLK5 / KLK7 + IL- 13 bispecific antibody compared to treatment with an anti-IL-13 antibody or an anti-IL-4 antibody, further indicating that the bispecific format of the anti-KLK5 / anti-KLK7 + IL- 13 targeting antibody does not alter efficacy.Example 3: Anti-KLK5 / KLK7 + IL-13 Bispecific Antibody Inhibits Primary Human Keratinocyte Barrier Disruption[000273] Corning Transwell inserts were treated with 100 uL of 50 ug / mL Rat Tail Collagen Type I for 1 hour and then washed with IX PBS. Primary Human Keratinocytes were seeded on collagen treated inserts at density of 50,000 cells / well. After 24 hours, culture media was replaced with culture media containing 1.5 mM calcium chloride to promote differentiation and cells were incubated for 72 hours. After 72 hours, culture media was replaced with 0.1 mM calcium chloride and differentiated cells were treated on both apical and basal side with mixture of 125 nM KLK5 and 125 nM KLK7 with and without inhibitory antibodies at concentrations ranging from 30 nM to 500 nM. 24 hours later, trans-epithelial resistance of the cell barrier was measured using Applied Biophysics TEER24 instrument. After trans-epithelial resistance measurement, culture media was replaced with fresh media and Img / mL FITC-Dextran dye was added to apical side of the trans well inserts. 24 hours later, media was collected from basal side and amount of dye migrated was measured byfluorescence at 487 nm excitation and 528 nm emission.[000274] KLK5 and KLK7 activation led to disruption of the epithelial barrier, decreasing the trans-epithelial resistance (TEER) and increasing the FITC-Dextran dye migration. This barrier disruption was inhibited by the anti-KLK5 / KLK7 + IL- 13 bispecific antibody (K13-0004), as well as the anti-KLK5 / KLK7 dual inhibitory antibody (KLK5 / KLK7-Dual-Ab4) which is demonstrated by dose dependent increase in trans- epithelial resistance (FIGs. 5A-5B) and decrease in dye migration (FIGs. 5C-5D).OTHER EMBODIMENTS[000275] All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.[000276] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.EQUIVALENTS AND SCOPE[000277] In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indica...

Claims

CLAIMSWhat is claimed is:

1. A bispecific antibody comprising an antigen- specific binding site that specifically binds KLK5 and KLK7 and an antigen- specific binding site that specifically binds to IL- 13 or a receptor thereof.

2. The bispecific antibody of claim 1, wherein the antigen- specific binding site that specifically binds KLK5 and KLK7 binds to the active sites of KLK5 and KLK7 and inhibits activity of the enzymes.

3. The bispecific antibody of claim 1 or 2, wherein the antigen- specific binding site that specifically binds to KLK5 and KLK7 comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the antibodies listed in Table la and Table lb.

4. The bispecific antibody of any one of claims 1-3, wherein the antigen-specific binding site that specifically binds KLK5 and KLK7 comprises:(a) a HC CDR1, a HC CDR2, a HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 7, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 8;(b) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 13, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14;(c) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 17, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14; or(d) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 21, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 14.

5. The bispecific antibody of any one of claims 1-4, wherein the antigen-specific binding site that specifically binds KLK5 and KLK7 comprises:(a) a HC CDR1 having the amino acid sequence of SEQ ID NO: 1, a HC CDR2 having the amino acid sequence of SEQ ID NO: 2, a HC CDR3 having the amino acid sequence of SEQ ID NO: 3, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 6;(b) a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 10, a HC CDR3 having the amino acid sequence of SEQ ID NO: 11, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12;(c) a HC CDR1 having the amino acid sequence of SEQ ID NO: 9, a HC CDR2 having the amino acid sequence of SEQ ID NO: 15, a HC CDR3 having the amino acid sequence of SEQ ID NO: 16, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12; or(d) a HC CDR1 having the amino acid sequence of SEQ ID NO: 18, a HC CDR2 having the amino acid sequence of SEQ ID NO: 19, a HC CDR3 having the amino acid sequence of SEQ ID NO: 20, a LC CDR1 having the amino acid sequence of SEQ ID NO: 4, a LC CDR2 having the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 12.

6. The bispecific antibody of any one of claims 1-5, wherein the antigen-specific binding site that specifically binds to KLK5 and KLK7 is of a VH and / or a VL of any one of the antibodies listed in Table la.

7. The bispecific antibody of any one of claims 1-6, wherein the antigen-specific binding site that specifically binds KLK5 and KLK7 comprises:(a) a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8;(b) a VH comprising the amino acid sequence of SEQ ID NO: 13, and a VL comprising the amino acid sequence of SEQ ID NO: 14;(c) a VH comprising the amino acid sequence of SEQ ID NO: 17, and a VL comprising the amino acid sequence of SEQ ID NO: 14; or(d) a VH comprising the amino acid sequence of SEQ ID NO: 21, and a VL comprising the amino acid sequence of SEQ ID NO: 14.

8. The bispecific antibody of any one of claims 1-7, wherein the antigen-specific binding site that specifically binds to IL- 13 or a receptor thereof comprises a HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and / or LC CDR3 of any one of the antibodies listed in Table 2.

9. The bispecific antibody of claim 8, wherein the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises:(a) a HC CDR1, a HC CDR2, a HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 53, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 54;(b) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 32, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 33;(c) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 74, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 75;(d) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 94, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 95;(e) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 114, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 115;(f) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 134, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 135; or(g) a HC CDR1, HC CDR2 and HC CDR3 of a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 657, and a LC CDR1, LC CDR2 and LC CDR3 of a light chain variable domain having the amino acid sequence of SEQ ID NO: 658.

10. The bispecific antibody of claim 8 or 9, wherein the antigen- specific binding site that specifically binds 11-13 or IL-13R comprises:(a) a HC CDR1 having the amino acid sequence of SEQ ID NO: 55, a HC CDR2 having the amino acid sequence of SEQ ID NO: 56, a HC CDR3 having the amino acid sequence of SEQ ID NO: 57, a LC CDR1 having the amino acid sequence of SEQ ID NO: 58, a LC CDR2 having the amino acid sequence of SEQ ID NO: 59, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 60;(b) a HC CDR1 having the amino acid sequence of SEQ ID NO: 61, a HC CDR2 having the amino acid sequence of SEQ ID NO: 62, a HC CDR3 having the amino acid sequence of SEQ ID NO: 63, a LC CDR1 having the amino acid sequence of SEQ ID NO: 64, a LC CDR2 having the amino acid sequence of SEQ ID NO: 65, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 66;(c) a HC CDR1 having the amino acid sequence of SEQ ID NO: 67, a HC CDR2 having the amino acid sequence of SEQ ID NO: 68, a HC CDR3 having the amino acid sequence of SEQ ID NO: 69, a LC CDR1 having the amino acid sequence of SEQ ID NO: 70, a LC CDR2 having the amino acid sequence of SEQ ID NO: 71, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 72;(d) a HC CDR1 having the amino acid sequence of SEQ ID NO: 34, a HC CDR2 having the amino acid sequence of SEQ ID NO: 35, a HC CDR3 having the amino acid sequence of SEQ ID NO: 36, a LC CDR1 having the amino acid sequence of SEQ ID NO: 37, a LC CDR2 having the amino acid sequence of SEQ ID NO: 38, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 39;(e) a HC CDR1 having the amino acid sequence of SEQ ID NO: 40, a HC CDR2 having the amino acid sequence of SEQ ID NO: 41, a HC CDR3 having the amino acid sequence of SEQ ID NO: 42, a LC CDR1 having the amino acid sequence of SEQ ID NO: 43, a LC CDR2 having the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 45;(f) a HC CDR1 having the amino acid sequence of SEQ ID NO: 46, a HC CDR2 having the amino acid sequence of SEQ ID NO: 47, a HC CDR3 having the amino acid sequence of SEQ ID NO: 48, a LC CDR1 having the amino acid sequence of SEQ ID NO: 49, a LC CDR2 having the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 51;(g) a HC CDR1 having the amino acid sequence of SEQ ID NO: 76, a HC CDR2 having the amino acid sequence of SEQ ID NO: 77, a HC CDR3 having the amino acid sequence of SEQ ID NO: 78, a LC CDR1 having the amino acid sequence of SEQ ID NO:79, a LC CDR2 having the amino acid sequence of SEQ ID NO: 80, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 81;(h) a HC CDR1 having the amino acid sequence of SEQ ID NO: 82, a HC CDR2 having the amino acid sequence of SEQ ID NO: 83, a HC CDR3 having the amino acid sequence of SEQ ID NO: 84, a LC CDR1 having the amino acid sequence of SEQ ID NO: 85, a LC CDR2 having the amino acid sequence of SEQ ID NO: 86, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 87;(i) a HC CDR1 having the amino acid sequence of SEQ ID NO: 88, a HC CDR2 having the amino acid sequence of SEQ ID NO: 89, a HC CDR3 having the amino acid sequence of SEQ ID NO: 90, a LC CDR1 having the amino acid sequence of SEQ ID NO: 91, a LC CDR2 having the amino acid sequence of SEQ ID NO: 92, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 93;(j) a HC CDR1 having the amino acid sequence of SEQ ID NO: 96, a HC CDR2 having the amino acid sequence of SEQ ID NO: 97, a HC CDR3 having the amino acid sequence of SEQ ID NO: 98, a LC CDR1 having the amino acid sequence of SEQ ID NO: 99, a LC CDR2 having the amino acid sequence of SEQ ID NO: 100, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 101;(k) a HC CDR1 having the amino acid sequence of SEQ ID NO: 102, a HC CDR2 having the amino acid sequence of SEQ ID NO: 103, a HC CDR3 having the amino acid sequence of SEQ ID NO: 104, a LC CDR1 having the amino acid sequence of SEQ ID NO: 105, a LC CDR2 having the amino acid sequence of SEQ ID NO: 106, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 107;(l) a HC CDR1 having the amino acid sequence of SEQ ID NO: 108, a HC CDR2 having the amino acid sequence of SEQ ID NO: 109, a HC CDR3 having the amino acid sequence of SEQ ID NO: 110, a LC CDR1 having the amino acid sequence of SEQ ID NO: 111, a LC CDR2 having the amino acid sequence of SEQ ID NO: 112, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 113;(m) a HC CDR1 having the amino acid sequence of SEQ ID NO: 116, a HC CDR2 having the amino acid sequence of SEQ ID NO: 117, a HC CDR3 having the amino acid sequence of SEQ ID NO: 118, a LC CDR1 having the amino acid sequence of SEQ ID NO: 119, a LC CDR2 having the amino acid sequence of SEQ ID NO: 120, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 121;(n) a HC CDR1 having the amino acid sequence of SEQ ID NO: 122, a HC CDR2 having the amino acid sequence of SEQ ID NO: 123, a HC CDR3 having the amino acidsequence of SEQ ID NO: 124, a LC CDR1 having the amino acid sequence of SEQ ID NO: 125, a LC CDR2 having the amino acid sequence of SEQ ID NO: 126, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 127;(o) a HC CDR1 having the amino acid sequence of SEQ ID NO: 128, a HC CDR2 having the amino acid sequence of SEQ ID NO: 129, a HC CDR3 having the amino acid sequence of SEQ ID NO: 130, a LC CDR1 having the amino acid sequence of SEQ ID NO: 131, a LC CDR2 having the amino acid sequence of SEQ ID NO: 132, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 133;(p) a HC CDR1 having the amino acid sequence of SEQ ID NO: 136, a HC CDR2 having the amino acid sequence of SEQ ID NO: 137, a HC CDR3 having the amino acid sequence of SEQ ID NO: 138, a LC CDR1 having the amino acid sequence of SEQ ID NO: 139, a LC CDR2 having the amino acid sequence of SEQ ID NO: 140, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 141;(q) a HC CDR1 having the amino acid sequence of SEQ ID NO: 142, a HC CDR2 having the amino acid sequence of SEQ ID NO: 143, a HC CDR3 having the amino acid sequence of SEQ ID NO: 144, a LC CDR1 having the amino acid sequence of SEQ ID NO: 145, a LC CDR2 having the amino acid sequence of SEQ ID NO: 146, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 147;(r) a HC CDR1 having the amino acid sequence of SEQ ID NO: 148, a HC CDR2 having the amino acid sequence of SEQ ID NO: 149, a HC CDR3 having the amino acid sequence of SEQ ID NO: 150, a LC CDR1 having the amino acid sequence of SEQ ID NO: 151, a LC CDR2 having the amino acid sequence of SEQ ID NO: 152, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 153;(s) a HC CDR1 having the amino acid sequence of SEQ ID NO: 655, a HC CDR2 having the amino acid sequence of SEQ ID NO: 41, a HC CDR3 having the amino acid sequence of SEQ ID NO: 42, a LC CDR1 having the amino acid sequence of SEQ ID NO: 43, a LC CDR2 having the amino acid sequence of SEQ ID NO: 44, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 45; or(t) a HC CDR1 having the amino acid sequence of SEQ ID NO: 656, a HC CDR2 having the amino acid sequence of SEQ ID NO: 47, a HC CDR3 having the amino acid sequence of SEQ ID NO: 48, a LC CDR1 having the amino acid sequence of SEQ ID NO: 49, a LC CDR2 having the amino acid sequence of SEQ ID NO: 50, and a LC CDR3 having the amino acid sequence of SEQ ID NO: 51.

11. The bispecific antibody of claim 9 or 10, wherein the antigen- specific binding site that specifically binds IL- 13 or IL-13R comprises:(a) a VH comprising the amino acid sequence of SEQ ID NO: 53 and a VL comprising the amino acid sequence of SEQ ID NO: 54;(b) a VH comprising the amino acid sequence of SEQ ID NO: 32, and a VL comprising the amino acid sequence of SEQ ID NO: 33;(c) a VH comprising the amino acid sequence of SEQ ID NO: 74, and a VL comprising the amino acid sequence of SEQ ID NO: 75;(d) a VH comprising the amino acid sequence of SEQ ID NO: 94, and a VL comprising the amino acid sequence of SEQ ID NO: 95;(e) a VH comprising the amino acid sequence of SEQ ID NO: 114, and a VL comprising the amino acid sequence of SEQ ID NO: 115;(f) a VH comprising the amino acid sequence of SEQ ID NO: 134, and a VL comprising the amino acid sequence of SEQ ID NO: 135; or(g) a VH comprising the amino acid sequence of SEQ ID NO: 657, and a VL comprising the amino acid sequence of SEQ ID NO: 658.

12. The bispecific antibody of any one of claims 1 to 11, wherein the antigen- specific binding site that specifically binds to IL- 13 or a receptor thereof is of a VH and / or a VL of any one of the antibodies in Table 2.

13. The bispecific antibody of any one of claims 1-12, wherein the bispecific antibody retains the binding affinity to KLK5 and KLK7 of no more than 20% difference relative to an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

14. The bispecific antibody of any one of claims 1-13, wherein the bispecific antibody retains the binding affinity of no more than 20% difference to IL- 13 signaling relative to an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

15. The bispecific antibody of any one of claims 1-14, wherein the bispecific antibody retains at least 80% of inhibitory activity to KLK5 and KLK7 relative to an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.425-16. The bispecific antibody of any one of claims 1-15, wherein the bispecific antibody retains at least 80% of inhibitory activity to IL- 13 signaling relative to an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

17. A composition comprising the bispecific antibody of any one of claims 1-16 and an acceptable carrier.

18. A method comprising administering the bispecific antibody of any one of claims 1-16 or the composition of claim 17 to a subject.

19. The method of claim 18, wherein the subject has a skin barrier defect.

20. A method of treating a skin barrier defect, the method comprising administering to a subject an effective amount of the bispecific antibody of any one of claims 1-16 or the composition of claim 17.

21. The method of claim 19 or 20, wherein the skin barrier defect is associated with Netherton syndrome, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, chronic pruritus of unknown origin (CPUO), dry skin, asthma (KLK5 specifically), ichthyosis vulgaris, or itch or chronic itch.

22. The method of any one of claims 18-21, wherein the subject has atopic dermatitis.

23. The method of claim 18-22, wherein the administration reduces ear thickness by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

24. The method of any one of claims 18-23, wherein the administration reduces ear thickness by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

25. The method of any one of claims 18-24, wherein the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

26. The method of any one of claims 18-25, wherein the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

27. The method of any one of claims 18-26, wherein the administration reduces skin erythema / hemorrhage by more than 30% relative to a subject administered an anti- KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

28. The method of any one of claims 18-27, wherein the administration reduces skin excoriation / erosion by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

29. The method of any one of claims 18-28, wherein the administration reduces skin scaling / dryness by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

30. The method of any one of claims 18-29, wherein the administration reduces skin scaling / dryness by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

31. The method of any one of claims 18-30, wherein the administration reduces skin edema by more than 30% relative to a subject administered an anti-KLK5 / KLK7 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

32. The method of any one of claims 18-31, wherein the administration reduces skin edema by more than 30% relative to a subject administered an anti-IL-13 antibody that comprises the same CDRs and / or VH / VL as the bispecific antibody.

Images